John C Byrd
#97,246
Most Influential Person Now
Researcher
John C Byrd's AcademicInfluence.com Rankings
John C Byrdengineering Degrees
Engineering
#2456
World Rank
#3372
Historical Rank
Electrical Engineering
#445
World Rank
#496
Historical Rank
John C Byrdcomputer-science Degrees
Computer Science
#3394
World Rank
#3560
Historical Rank
Data Science
#29
World Rank
#29
Historical Rank
Computational Linguistics
#163
World Rank
#167
Historical Rank
Machine Learning
#393
World Rank
#398
Historical Rank
Download Badge
Engineering Computer Science
John C Byrd's Degrees
- PhD Computer Science Stanford University
- Masters Electrical Engineering University of California, Berkeley
Similar Degrees You Can Earn
Why Is John C Byrd Influential?
(Suggest an Edit or Addition)John C Byrd's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling (2000) (9767)
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. (2009) (2236)
- Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. (2013) (1980)
- Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). (2002) (1610)
- Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. (2014) (1363)
- Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia (2001) (1215)
- Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. (2002) (1010)
- ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. (2004) (973)
- Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. (2014) (966)
- iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. (2018) (874)
- MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. (2009) (751)
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. (2011) (748)
- Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. (1998) (731)
- CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. (2011) (724)
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. (2010) (722)
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. (2016) (707)
- Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. (2015) (626)
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. (2013) (621)
- Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review. (1995) (601)
- Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). (2003) (598)
- Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. (2014) (590)
- Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. (2008) (577)
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL (2018) (575)
- Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. (2010) (554)
- Adult Burkitt leukemia and lymphoma. (2004) (552)
- Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. (2001) (548)
- Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. (2015) (492)
- Genetic heterogeneity of diffuse large B-cell lymphoma (2013) (488)
- Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. (2017) (484)
- Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. (2004) (460)
- Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine (2010) (458)
- Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. (2005) (449)
- Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. (2014) (446)
- The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. (2002) (418)
- Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. (2007) (404)
- A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. (2004) (402)
- Downregulation of Death-Associated Protein Kinase 1 (DAPK1) in Chronic Lymphocytic Leukemia (2007) (391)
- The B-cell receptor signaling pathway as a therapeutic target in CLL. (2012) (378)
- Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. (2007) (366)
- Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. (2016) (359)
- NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. (2010) (355)
- International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia (2007) (352)
- FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. (2007) (349)
- Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. (2018) (325)
- Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. (2008) (322)
- Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. (2007) (310)
- Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. (2006) (303)
- Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. (1999) (303)
- Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. (1998) (302)
- Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. (1999) (290)
- M6P/IGF2R imprinting evolution in mammals. (2000) (278)
- Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. (2018) (276)
- Low levels of miR‐92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma (2007) (273)
- Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. (2014) (272)
- Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial (2020) (267)
- Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. (2006) (260)
- Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. (2012) (258)
- Ibrutinib treatment improves T cell number and function in CLL patients (2017) (244)
- BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. (2017) (239)
- Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. (2009) (238)
- DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia (2016) (237)
- Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (2019) (236)
- Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. (2010) (233)
- Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. (1997) (232)
- Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). (1997) (231)
- A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). (2014) (224)
- Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. (2003) (215)
- Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. (2000) (211)
- FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia (2004) (208)
- Expression and prognostic impact of lncRNAs in acute myeloid leukemia (2014) (205)
- Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL (2017) (205)
- Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia (2005) (203)
- Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. (2014) (202)
- Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. (2004) (202)
- A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide (2009) (201)
- Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. (2003) (197)
- Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation. (2018) (196)
- Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. (2014) (194)
- PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. (2013) (193)
- Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. (2009) (189)
- Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). (2014) (188)
- Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. (2014) (185)
- Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials (2017) (182)
- Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. (2012) (177)
- TGF-β Utilizes SMAD3 to Inhibit CD16-Mediated IFN-γ Production and Antibody-Dependent Cellular Cytotoxicity in Human NK Cells1 (2008) (175)
- Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. (2003) (172)
- Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. (2014) (171)
- Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. (2009) (170)
- Epigenetic Profiling in Chronic Lymphocytic Leukemia Reveals Novel Methylation Targets (2004) (167)
- Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK–STAT pathway in Sézary syndrome (2015) (167)
- Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia (2007) (164)
- Frequency and type of serious infections in fludarabine‐refractory B‐cell chronic lymphocytic leukemia and small lymphocytic lymphoma (2002) (164)
- Flavopiridol Induces Apoptosis in Chronic Lymphocytic Leukemia Cells Via Activation of Caspase-3 Without Evidence of bcl-2 Modulation or Dependence on Functional p53 (1998) (161)
- Chronic lymphocytic leukemia. (2010) (160)
- Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. (1999) (160)
- Daunorubicin-Loaded DNA Origami Nanostructures Circumvent Drug-Resistance Mechanisms in a Leukemia Model. (2016) (159)
- FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. (2008) (158)
- The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. (2009) (157)
- Targeted Delivery of microRNA-29b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia (2013) (155)
- Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells (2003) (154)
- Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. (2007) (151)
- Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. (2019) (148)
- Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. (2014) (148)
- Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment. (2016) (147)
- Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. (2008) (147)
- Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. (2005) (143)
- Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. (2010) (143)
- Campath-1H monoclonal antibody therapy (2000) (143)
- Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. (2005) (142)
- Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. (2008) (140)
- In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. (2015) (139)
- Mcl-1 Is a Relevant Therapeutic Target in Acute and Chronic Lymphoid Malignancies: Down-Regulation Enhances Rituximab-Mediated Apoptosis and Complement-Dependent Cytotoxicity (2007) (138)
- Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. (2015) (138)
- Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. (2014) (138)
- Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. (2014) (136)
- Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling. (2015) (136)
- Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. (2012) (134)
- Non‐hodgkin's lymphomas (2010) (133)
- Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. (2006) (133)
- The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells (2004) (133)
- Treatment of Relapsed Chronic Lymphocytic Leukemia by 72-Hour Continuous Infusion or 1-Hour Bolus Infusion of Flavopiridol: Results from Cancer and Leukemia Group B Study 19805 (2005) (132)
- Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. (2011) (131)
- Non-Hodgkin's lymphomas, version 4.2014. (2014) (131)
- Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. (2019) (131)
- Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. (2015) (131)
- The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. (2010) (130)
- Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemia. (2012) (130)
- Regulation of acute graft-versus-host disease by microRNA-155. (2010) (129)
- Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. (2012) (128)
- NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. (2016) (127)
- CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia. (2006) (127)
- Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. (2010) (127)
- Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor–Mediated Natural Killer Cell Function (2018) (126)
- CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome? (1999) (126)
- In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation (2013) (124)
- Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia (2007) (123)
- Hypertension and Incident Cardiovascular Events Following Ibrutinib Initiation. (2019) (123)
- A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. (2015) (122)
- CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom’s Macroglobulinemia (2001) (120)
- Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. (2019) (120)
- Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial (2021) (120)
- CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. (2010) (118)
- Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. (2017) (116)
- Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism (2006) (116)
- Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation. (2015) (115)
- Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. (1998) (115)
- Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. (2014) (114)
- Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. (2008) (113)
- Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. (2012) (112)
- Renal medullary carcinoma: Clinical and therapeutic aspects of a newly described tumor (1996) (111)
- Pentostatin in steroid-refractory acute graft-versus-host disease. (2005) (111)
- Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia (2012) (111)
- Histone Deacetylase Inhibitors Stimulate Histone H3 Lysine 4 Methylation in Part Via Transcriptional Repression of Histone H3 Lysine 4 Demethylases (2011) (111)
- TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. (2008) (110)
- 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. (2008) (110)
- Opportunistic pulmonary infections with fludarabine in previously treated patients with low‐grade lymphoid malignancies: A role for pneumocystis carinii pneumonia prophylaxis (1995) (110)
- Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (2010) (109)
- Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. (2004) (109)
- Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. (2010) (109)
- TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. (2005) (108)
- Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia (2009) (108)
- Phase 1 Study of Lumiliximab with Detailed Pharmacokinetic and Pharmacodynamic Measurements in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (2007) (108)
- Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity. (1999) (107)
- FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling. (2008) (106)
- Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. (2019) (105)
- Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. (2014) (105)
- Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. (2017) (104)
- Next generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematologic malignancies (2015) (103)
- ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. (2012) (103)
- IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. (2008) (102)
- Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia (2016) (100)
- Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study. (2007) (100)
- The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. (2011) (100)
- Recurrent granulocytic sarcoma. An unusual variation of acute myelogenous leukemia associated with 8;21 chromosomal translocation and blast expression of the neural cell adhesion molecule (1994) (99)
- Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. (2005) (99)
- Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. (2003) (98)
- The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia (2016) (97)
- IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. (2014) (97)
- A Phase 2 Study of Rituximab in Combination with Recombinant Interleukin-2 for Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma (2006) (96)
- Update on the biology of chronic lymphocytic leukemia. (2000) (95)
- How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. (2019) (95)
- Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. (2004) (95)
- Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2. (2009) (94)
- Dinaciclib is a Novel Cyclin Dependent Kinase Inhibitor with Significant Clinical Activity in Relapsed and Refractory Chronic Lymphocytic Leukemia (2015) (94)
- Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. (2010) (92)
- Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study (2020) (91)
- Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia (2009) (89)
- The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. (2018) (86)
- Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. (2003) (86)
- Dose escalation of lenalidomide in relapsed or refractory acute leukemias. (2010) (86)
- Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia. (2018) (85)
- Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. (2012) (85)
- Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia. (2015) (84)
- Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Properties (2013) (83)
- Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. (2010) (82)
- Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. (2011) (81)
- Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (2016) (80)
- BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor. (2018) (80)
- Magnetic tweezers-based 3D microchannel electroporation for high-throughput gene transfection in living cells. (2015) (80)
- Combination Immunotherapy of B-Cell Non-Hodgkin’s Lymphoma with Rituximab and Interleukin-2 (2004) (79)
- Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. (2008) (79)
- Phase II study of single‐agent bortezomib for the treatment of patients with fludarabine‐refractory B‐cell chronic lymphocytic leukemia (2006) (79)
- FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. (2005) (78)
- The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells (2012) (78)
- Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. (2019) (78)
- Acute myeloid leukemia clinical practice guidelines in oncology. (2006) (77)
- Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia. (2011) (77)
- Antitumor effects of OSU‐2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma (2011) (77)
- Diffuse Large B-Cell Lymphoma Version 1.2016. (2016) (76)
- Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. (2009) (76)
- Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies (2018) (76)
- Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. (2009) (76)
- Delivery of antisense oligodeoxyribonucleotide lipopolyplex nanoparticles assembled by microfluidic hydrodynamic focusing. (2010) (76)
- Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2'-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. (2006) (75)
- Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines. (2008) (74)
- Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance. (2005) (74)
- Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia (2016) (74)
- Efflux of Depsipeptide FK228 (FR901228, NSC-630176) Is Mediated by P-Glycoprotein and Multidrug Resistance-Associated Protein 1 (2005) (74)
- Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002 (2014) (74)
- A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. (2012) (74)
- Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies. (2013) (73)
- Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL. (2011) (73)
- A Phase I Biological Study of MG98, an Oligodeoxynucleotide Antisense to DNA Methyltransferase 1, in Patients with High-Risk Myelodysplasia and Acute Myeloid Leukemia (2008) (72)
- Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. (2009) (72)
- Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. (2018) (72)
- Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate (2018) (72)
- Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes. (2002) (71)
- Non-Hodgkin's lymphomas, version 1.2013. (2013) (71)
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. (2020) (71)
- Cholesterol as a bilayer anchor for PEGylation and targeting ligand in folate-receptor-targeted liposomes. (2007) (71)
- Accurate quantification of DNA methylation using combined bisulfite restriction analysis coupled with the Agilent 2100 Bioanalyzer platform (2006) (71)
- Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies. (2018) (71)
- Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method (2007) (70)
- Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. (2016) (70)
- Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. (2008) (69)
- Chemoresistance to Depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-Ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] Is Mediated by Reversible MDR1 Induction in Human Cancer Cell Lines (2005) (68)
- A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism. (2004) (68)
- Emerging drug profile: cyclin-dependent kinase inhibitors (2013) (67)
- Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial (2020) (67)
- Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis (2018) (67)
- Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. (2014) (66)
- A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. (2014) (66)
- Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells. (2004) (66)
- Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102). (2009) (66)
- Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers. (2016) (64)
- Methylation and Silencing of Protein Tyrosine Phosphatase Receptor Type O in Chronic Lymphocytic Leukemia (2007) (64)
- Differential expression of histone post-translational modifications in acute myeloid and chronic lymphocytic leukemia determined by high-pressure liquid chromatography and mass spectrometry (2003) (64)
- Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. (2016) (64)
- Rituximab in B-cell chronic lymphocytic leukemia. (2003) (63)
- Narrative Review: Initial Management of Newly Diagnosed, Early-Stage Chronic Lymphocytic Leukemia (2006) (63)
- Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma (2010) (62)
- The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study (2011) (62)
- Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality (2007) (61)
- Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non‐Hodgkin lymphoma: dose‐limiting myelosuppression without evidence of DNA hypomethylation (2010) (61)
- The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia (2017) (61)
- How will B-cell-receptor-targeted therapies change future CLL therapy? (2014) (61)
- Resistance to the Translation Initiation Inhibitor Silvestrol is Mediated by ABCB1/P-Glycoprotein Overexpression in Acute Lymphoblastic Leukemia Cells (2011) (61)
- Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goals. (1998) (60)
- A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders (2012) (60)
- Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. (2013) (60)
- TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia (2015) (59)
- Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. (2016) (59)
- Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies (2019) (59)
- Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. (2004) (58)
- ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL). (2019) (58)
- Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia. (2005) (58)
- Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium. (2008) (58)
- Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single‐agent ibrutinib (2017) (57)
- Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism. (2010) (57)
- Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. (2013) (57)
- Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia (2013) (57)
- The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo (2010) (57)
- FTY720 Shows Promising In vitro and In vivo Preclinical Activity by Downmodulating Cyclin D1 and Phospho-Akt in Mantle Cell Lymphoma (2010) (57)
- Complex karyotype predicts for inferior outcomes following reduced‐intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia (2012) (56)
- NF-κB Functions in Tumor Initiation by Suppressing the Surveillance of Both Innate and Adaptive Immune Cells (2014) (56)
- Circulating miRNA markers show promise as new prognosticators for multiple myeloma (2014) (55)
- Preliminary Results From A Phase I Dose Escalation Study to Determine the Maximum Tolerated Dose of Plerixafor In Combination with Rituximab In Patients with Relapsed Chronic Lymphocytic Leukemia (2010) (55)
- Extramedullary myeloid cell tumors in myelodysplastic-syndromes: not a true indication of impending acute myeloid leukemia. (1996) (55)
- Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies (2019) (55)
- Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2017) (55)
- The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia (2015) (55)
- Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant. (2019) (55)
- First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL (2018) (55)
- NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. (2017) (55)
- A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701 (2013) (55)
- The Bruton's Tyrosine Kinase Inhibitor, PCI-32765, Is Well Tolerated and Demonstrates Promising Clinical Activity In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): An Update on Ongoing Phase 1 Studies (2010) (55)
- Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3. (2005) (54)
- Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function* (2015) (54)
- Epigenetic silencing of miR‐708 enhances NF‐κB signaling in chronic lymphocytic leukemia (2015) (54)
- Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. (2012) (54)
- A single‐institution retrospective cohort study of first‐line R‐EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor (2018) (54)
- Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma (2011) (53)
- A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. (2014) (53)
- Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias (2010) (53)
- Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies (2014) (53)
- Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia (2014) (53)
- Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells (2014) (53)
- Ibrutinib in relapsed chronic lymphocytic leukemia. (2013) (53)
- Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years (2020) (52)
- Flavopiridol Pharmacogenetics: Clinical and Functional Evidence for the Role of SLCO1B1/OATP1B1 in Flavopiridol Disposition (2010) (52)
- Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. (2012) (52)
- Atypical lymphocytic lobular panniculitis (2004) (52)
- Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer (2017) (52)
- Involvement of RhoH GTPase in the Development of B-Cell Chronic Lymphocytic Leukemia (2009) (52)
- Flavopiridol in the treatment of chronic lymphocytic leukemia (2007) (52)
- Final results of a phase I study of idelalisib (GSE1101) a selective inhibitor of PI3Kδ, in patients with relapsed or refractory CLL. (2013) (52)
- RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans. (2012) (51)
- Patients with isolated trisomy 8 in acute myeloid leukemia are not cured with cytarabine-based chemotherapy: results from Cancer and Leukemia Group B 8461. (1998) (51)
- Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia (2013) (50)
- Chronic lymphocytic leukemia. (2004) (50)
- Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma (2016) (49)
- Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. (2015) (49)
- Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study. (2010) (49)
- A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211 (2003) (49)
- FTY 720 , a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome – positive acute lymphocytic leukemia (2007) (49)
- Characterization of a New Chronic Lymphocytic Leukemia Cell Line for Mechanistic In Vitro and In Vivo Studies Relevant to Disease (2013) (48)
- Acalabrutinib Plus Obinutuzumab in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia. (2020) (48)
- New Strategies in Chronic Lymphocytic Leukemia: Shifting Treatment Paradigms (2014) (48)
- PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment (2017) (48)
- Tetraspanins as therapeutic targets in hematological malignancy: a concise review (2015) (48)
- PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL. (2014) (47)
- Detection of extracellular RNAs in cancer and viral infection via tethered cationic lipoplex nanoparticles containing molecular beacons. (2013) (47)
- NCCN guidelines® insights chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017: Featured updates to the NCCN guidelines (2017) (47)
- Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. (2015) (46)
- Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia (2016) (46)
- Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically (2019) (46)
- Non-Hodgkin's lymphomas, version 2.2014. (2014) (46)
- Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia. (1995) (45)
- Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing. (2013) (45)
- Quantitative analyses of DAPK1 methylation in AML and MDS (2012) (45)
- MicroRNA-29b mediates altered innate immune development in acute leukemia. (2016) (45)
- Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features (2012) (45)
- Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study (2017) (45)
- Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations (2019) (45)
- Targeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pH-sensitive lipopolyplex nanoparticles: a novel oligonucleotide-based therapeutic strategy in acute myeloid leukemia. (2010) (45)
- A novel liposomal formulation of flavopiridol. (2009) (44)
- Reciprocal Regulation of Activating and Inhibitory Fcγ Receptors by TLR7/8 Activation: Implications for Tumor Immunotherapy (2010) (44)
- Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study (1999) (44)
- Flavopiridol in chronic lymphocytic leukemia: a concise review. (2009) (44)
- Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS/MS. (2007) (44)
- Risk Factors for Tumor Lysis Syndrome in patients with Chronic Lymphocytic Leukemia Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol (2011) (44)
- FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death. (2011) (44)
- Pentostatin and rituximab therapy for previously untreated patients with B‐cell chronic lymphocytic leukemia (2010) (44)
- Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies. (2010) (43)
- Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. (2019) (42)
- Cellular Uptake and Intracellular Levels of the Bcl-2 Antisense G3139 in Cultured Cells and Treated Patients with Acute Myeloid Leukemia (2005) (42)
- Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia (2008) (42)
- Evidence of Clinical Activity in a Phase 1 Study of CAL-101, An Oral P110Δ Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies. (2009) (41)
- Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. (2011) (41)
- Epigenetics in chronic lymphocytic leukemia. (2006) (41)
- Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia (2014) (41)
- Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse (2012) (41)
- FcgammaR-induced production of superoxide and inflammatory cytokines is differentially regulated by SHIP through its influence on PI3K and/or Ras/Erk pathways. (2006) (41)
- A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas (2017) (41)
- Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia. (2020) (40)
- Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. (2018) (40)
- Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells. (2013) (40)
- Comparison of Results from a Phase 1/2 Study of Lumiliximab (Anti-CD23) in Combination with FCR for Patients with Relapsed CLL with Published FCR Results. (2006) (40)
- Treatment of relapsed chronic lymphocytic leukemia: old and new therapies. (2006) (40)
- The humanized CD40 antibody SGN‐40 demonstrates pre‐clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia (2009) (40)
- Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia (2005) (40)
- Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma (2009) (40)
- Sp1/NF κ B/HDAC/ miR-29b Regulatory Network in KIT-driven Myeloid Leukemia (2010) (40)
- Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia (2015) (40)
- HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide (2014) (39)
- Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. (2010) (39)
- Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study. (2011) (39)
- Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma, (2010) (39)
- Novel therapies for chronic lymphocytic leukemia in the 21st century. (2000) (39)
- Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome. (2020) (38)
- Anaphylactoid reactions to methotrexate (1996) (38)
- Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia (2022) (37)
- Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. (2010) (37)
- Liquid chromatography mass spectrometry profiling of histones. (2007) (37)
- Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL). (2013) (37)
- Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate. (2011) (36)
- Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy (2015) (36)
- Granzyme B Expression Is Enhanced in Human Monocytes by TLR8 Agonists and Contributes to Antibody-Dependent Cellular Cytotoxicity (2015) (36)
- Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials (2018) (36)
- Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia (2017) (36)
- Mitochondria control of cell death induced by anti-HLA-DR antibodies (2003) (35)
- A phase I trial of flavopiridol in relapsed multiple myeloma (2014) (35)
- Consolidation Therapy with Subcutaneous (SC) Alemtuzumab Results in Severe Infectious Toxicity in Previously Untreated CLL Patients Who Achieve a Complete Response (CR) after Fludarabine and Rituximab (FR) Induction Therapy: Interim Safety Analysis of the CALGB Study 10101. (2007) (35)
- Otlertuzumab (TRU‐016), an anti‐CD37 monospecific ADAPTIR™ therapeutic protein, for relapsed or refractory NHL patients (2015) (35)
- Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia. (2007) (35)
- Clinical Activity of Duvelisib (IPI-145), a Phosphoinositide-3-Kinase-δ,γ Inhibitor, in Patients Previously Treated with Ibrutinib (2014) (34)
- Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia (2014) (34)
- The Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Cytotoxicity and an Atypical NF-κB Response in Chronic Lymphocytic Leukemia Cells (2013) (34)
- Functional Role of mTORC2 versus Integrin-Linked Kinase in Mediating Ser473-Akt Phosphorylation in PTEN-Negative Prostate and Breast Cancer Cell Lines (2013) (34)
- CD19 CAR-T cells combined with ibrutinib to induce complete remission in CLL. (2017) (34)
- Di erent types of di use large b-cell lymphoma identi ed by gene expression pro ling (2000) (34)
- UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism. (2001) (34)
- Differentiation of PC12 pheochromocytoma cells by sodium butyrate. (1987) (33)
- Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies (2012) (33)
- A novel liposomal formulation of FTY720 (fingolimod) for promising enhanced targeted delivery. (2014) (33)
- Molecular profiling of chronic lymphocytic leukaemia: genetics meets epigenetics to identify predisposing genes (2007) (33)
- The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model (2014) (33)
- Role of B cell receptor signaling in IL‐10 production by normal and malignant B‐1 cells (2015) (33)
- Autophagy and ER stress play an essential role in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol (2013) (33)
- Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. (2020) (33)
- A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia (2009) (33)
- The Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL) (2014) (33)
- Acalabrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia. (2021) (33)
- Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B cell cytotoxicity in chronic lymphocytic leukemia (2014) (33)
- Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib. (2019) (33)
- Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia (2016) (33)
- Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A (2020) (33)
- T-cell transcriptional profiling and immunophenotyping uncover LAG3 as a potential significant target of immune modulation in multiple myeloma. (2020) (33)
- Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers. (2002) (32)
- Second Cancer Incidence in CLL Patients Receiving BTK Inhibitors (2019) (32)
- Development and Validation of a Highly Sensitive Liquid Chromatography/Mass Spectrometry Method for Simultaneous Quantification of Lenalidomide and Flavopiridol in Human Plasma (2008) (32)
- Autologous hematopoietic stem cell transplant induces the molecular aging of T-cells in multiple myeloma (2015) (32)
- Effi cacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes : a randomised , open-label , phase III study (2012) (31)
- Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATETM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2014) (31)
- The evolving role of Alemtuzumab in management of patients with CLL (2005) (31)
- Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia. (2019) (31)
- Phase I Trial of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Advanced Acute Myelogenous Leukemia (AML) (2013) (31)
- Epinephrine synthesis in the PC12 pheochromocytoma cell line. (1986) (31)
- PI3K p110&dgr; inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression (2018) (31)
- Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma (2016) (31)
- Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403 (2015) (31)
- Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. (2019) (31)
- Acalabrutinib Monotherapy in Patients with Richter Transformation from the Phase 1/2 ACE-CL-001 Clinical Study (2016) (31)
- Signalling to drug resistance in CLL. (2010) (31)
- Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results from the Phase 1/2 ACE-CL-001 Study (2017) (30)
- Detection of Epstein-Barr virus in transformations of low-grade B-cell lymphomas after fludarabine treatment. (1997) (30)
- A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors (2012) (30)
- Targeting BTK through microRNA in chronic lymphocytic leukemia. (2016) (30)
- Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells (2016) (30)
- Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations. (2020) (30)
- CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia. (2001) (30)
- Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2018) (30)
- KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis. (2003) (30)
- Synthetic microRNA cassette dosing: pharmacokinetics, tissue distribution and bioactivity. (2012) (29)
- The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors (2018) (29)
- Update on the Phase I Study of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity and Feasibility of Long-Term Administration (2010) (29)
- Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia (2017) (29)
- First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia. (2021) (29)
- Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center (2017) (29)
- Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non‐Hodgkin's lymphoma (2014) (29)
- The Raf Kinase Inhibitor Sorafenib Inhibits JAK–STAT Signal Transduction in Human Immune Cells (2008) (29)
- Identification of thiols and glutathione conjugates of depsipeptide FK228 (FR901228), a novel histone protein deacetylase inhibitor, in the blood. (2003) (29)
- Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia (2010) (29)
- Rituximab: converging mechanisms of action in non-Hodgkin's lymphoma? (2003) (29)
- Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. (2017) (29)
- Non-Hodgkin's Lymphomas, version 3.2012: Featured updates to the NCCN guidelines (2012) (29)
- Proenkephalin gene expression in the PC12 pheochromocytoma cell line: stimulation by sodium butyrate. (1987) (28)
- Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia. (2013) (28)
- Changing the way we think about chronic lymphocytic leukemia. (2005) (28)
- A Novel Raji-Burkitt's Lymphoma Model for Preclinical and Mechanistic Evaluation of CD52-Targeted Immunotherapeutic Agents (2008) (28)
- Differential effects of IL-2 and IL-21 on expansion of the CD4+CD25+Foxp3+ T regulatory cells with redundant roles in natural killer cell mediated antibody dependent cellular cytotoxicity in chronic lymphocytic leukemia (2010) (28)
- Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro. (2010) (28)
- A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL) (2012) (28)
- A randomized, open‐label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia (2014) (28)
- Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia (2010) (28)
- A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy (2016) (28)
- Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia (2017) (28)
- Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom’s Macroglobulinemia (WM) (2013) (27)
- Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. (2020) (27)
- Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia (2013) (27)
- Phase 1b Results of a Phase 1b/2 Study of Obinutuzmab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) (2016) (27)
- The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): Interim results of a phase Ib/II study. (2012) (27)
- Increasing the complexity of chromatin: functionally distinct roles for replication-dependent histone H2A isoforms in cell proliferation and carcinogenesis (2013) (27)
- Pooled Analysis of Safety Data from Clinical Trials Evaluating Acalabrutinib Monotherapy in Hematologic Malignancies (2017) (27)
- NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome (2018) (27)
- Initial Results of the Phase 2 Treatment Naive Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia (2017) (27)
- Combination Chemotherapy with Pentostatin, Cyclophosphamide and Rituximab Induces High Rate of Remissions Including Complete Responses and Achievement of Minimal Residual Disease in Previously Untreated B-Chronic Lymphocytic Leukemia. (2004) (27)
- Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia. (2020) (27)
- Herpes zoster and lymphopenia associated with sodium stibogluconate therapy for cutaneous leishmaniasis. (1998) (27)
- Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria. (2007) (26)
- Validation of an LC‐MS based approach for profiling histones in chronic lymphocytic leukemia (2009) (26)
- Quantitative profiling of histone post-translational modifications by stable isotope labeling. (2007) (26)
- Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901 (2009) (26)
- Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. (2017) (26)
- Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Ofa First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (2013) (26)
- Rituximab and 17‐allylamino‐17‐demethoxygeldanamycin induce synergistic apoptosis in B‐cell chronic lymphocytic leukaemia (2007) (26)
- The combination of milatuzumab, a humanized anti‐CD74 antibody, and veltuzumab, a humanized anti‐CD20 antibody, demonstrates activity in patients with relapsed and refractory B‐cell non‐Hodgkin lymphoma (2015) (26)
- Clinical and functional significance of circular RNAs in cytogenetically normal AML. (2020) (26)
- Preliminary evidence of clinical activity in a phase I study of CAL-101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3-kinase (P13K), in patients with select hematologic malignancies. (2009) (25)
- Epigenetic alterations in a murine model for chronic lymphocytic leukemia (2009) (25)
- NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. (2017) (25)
- Identification of endoplasmic reticulum stress-inducing agents by antagonizing autophagy: a new potential strategy for identification of anti-cancer therapeutics in B-cell malignancies (2013) (25)
- Resistance mechanisms to SYK inhibition in acute myeloid leukemia. (2019) (25)
- Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia (2018) (25)
- The B-cell receptor pathway: a critical component of healthy and malignant immune biology. (2014) (25)
- Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia (2014) (25)
- Germline Allele-Specific Expression of DAPK1 in Chronic Lymphocytic Leukemia (2013) (24)
- Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL (2010) (24)
- Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma. (2009) (24)
- Obinutuzumab (GA101) 1,000 mg versus 2,000 mg in patients with chronic lymphocytic leukemia (CLL): Results of the phase II GAGE (GAO4768g) trial. (2014) (24)
- Pharmacokinetics and Tissue Disposition of Lenalidomide in Mice (2012) (24)
- Use of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemia (2006) (23)
- Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. (2019) (23)
- Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study (2020) (23)
- Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia (2017) (23)
- Impact of Targeted Therapy on Outcome of Chronic Lymphocytic Leukemia Patients with Relapsed Del(17p13.1) Karyotype at a Single Center (2014) (23)
- Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium. (2010) (22)
- CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia. (2015) (22)
- CS1-directed monoclonal antibody therapy for multiple myeloma. (2012) (22)
- A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol (2013) (22)
- Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202 (2018) (22)
- Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis (2019) (22)
- Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 Study (2018) (22)
- Phase II Trial of Ofatumumab (OFA) for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (2011) (22)
- Stem-cell transplantation in chronic lymphocytic leukemia: the time for designing randomized studies has arrived. (1999) (21)
- Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality. (2017) (21)
- Hyperglycemia in Patients with Acute Myeloid Leukemia Is Associated with Increased Hospital Mortality. (2006) (21)
- Independent evaluation of ibrutinib efficacy 3 years post-initiation of monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic leukemia including deletion 17p disease. (2014) (21)
- Targeting myeloid-derived suppressor cells using a novel adenosine monophosphate-activated protein kinase (AMPK) activator (2016) (21)
- Acalabrutinib Monotherapy in Patients with Ibrutinib Intolerance: Results from the Phase 1/2 ACE-CL-001 Clinical Study (2016) (21)
- Cells, cytokines, chemokines, and cancer stress: A biobehavioral study of patients with chronic lymphocytic leukemia (2018) (21)
- Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression (2020) (21)
- Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt – Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002 (2010) (21)
- Depsipeptide ( FR 901228 ) : A Novel Therapeutic Agent With Selective , In Vitro Activity Against Human B-Cell Chronic Lymphocytic Leukemia Cells (1999) (21)
- A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma (2019) (21)
- The international Prognostic Index for patients with CLL (CLL-IPI) : An international meta-analysis (2015) (21)
- Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia (2020) (21)
- Flavopiridol Administered as a Pharmacologically-Derived Schedule Demonstrates Marked Clinical Activity in Refractory, Genetically High Risk, Chronic Lymphocytic Leukemia (CLL). (2004) (21)
- Histone H4 acetylation dynamics determined by stable isotope labeling with amino acids in cell culture and mass spectrometry. (2007) (20)
- AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia. (2011) (20)
- Rituximab in chronic lymphocytic leukemia. (2010) (20)
- Safety and Efficacy Results from a Phase I Trial of Single-Agent Lumiliximab (Anti-CD23 Antibody) for Chronic Lymphocytic Leukemia. (2004) (20)
- Association of disease progression on ibrutinib therapy with the acquisition of resistance mutations: A single-center experience of 267 patients. (2014) (20)
- Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers. (2002) (20)
- Individual differences in physical symptom burden and psychological responses in individuals with chronic lymphocytic leukemia (2016) (20)
- Second malignancies in B‐cell chronic lymphocytic leukaemia: possible association with human papilloma virus (2010) (20)
- Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) Is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102). (2005) (20)
- A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2014) (20)
- High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia (2005) (19)
- Decitabine in chronic leukemias. (2005) (19)
- Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue. (2014) (19)
- A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells (2016) (19)
- Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia. (2016) (19)
- Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia (2009) (19)
- Alemtuzumab Increases Serious Infections in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine-Based Therapy: A Comparative Analysis of 3 Cancer and Leukemia Group B Studies (CALGB 9011, 9712, 19901). (2007) (19)
- Reprogramming Nurse-like Cells with Interferon γ to Interrupt Chronic Lymphocytic Leukemia Cell Survival* (2016) (19)
- Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia (2018) (19)
- Phase I/II, Open-Label, Dose-Escalating Study of MDX-060 Administered Weekly for 4 Weeks in Subjects with Refractory/Relapsed CD30 Positive Lymphoma. (2004) (19)
- Hematologic and Immunologic Function and Patient Well-Being for the Phase III RESONATETM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2014) (19)
- Liposomal coencapsulated fludarabine and mitoxantrone for lymphoproliferative disorder treatment. (2008) (19)
- Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials (2018) (19)
- The PtdIns 3-Kinase/Akt Pathway Regulates Macrophage-Mediated ADCC against B Cell Lymphoma (2009) (19)
- Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML (2019) (19)
- How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic (2020) (19)
- ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity (2015) (18)
- Pharmacokinetics and Pharmacodynamics from a First-in-Human Phase 1 Dose Escalation Study with Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12), in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia. (2006) (18)
- A Novel Ultrasensitive Hybridization-Based ELISA Method for 2-Methoxyphosphorothiolate MicroRNAs and Its In vitro and In vivo Application (2010) (18)
- Non-Hodgkin's Lymphomas, version 3.2012. (2012) (18)
- Clonal selection of CD56+ t(8;21) AML blasts: further suggestion of the adverse clinical significance of this biological marker? (1999) (18)
- Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphoma. (2015) (18)
- Phase 2 Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIRTM Protein, In Combination With Bendamustine Vs Bendamustine Alone In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) (2013) (18)
- Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy (2019) (18)
- Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL) (2015) (18)
- Response: Additional data needed for a better understanding of the potential relationship between atrial fibrillation and ibrutinib. (2015) (18)
- OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. (2015) (18)
- ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in CLL mouse model. (2019) (18)
- Dinaciclib (SCH 727965) Is a Novel Cyclin-Dependent Kinase (CDK) Inhibitor That Exhibits Activity In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL) (2013) (18)
- High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation. (2006) (18)
- Successful treatment of invasive aspergillosis complicating prolonged treatment-related neutropenia in acute myelogenous leukemia with amphotericin B lipid complex. (1995) (18)
- Pancreatitis during therapy of acute myeloid leukemia: cytarabine related? (1999) (18)
- Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461. (2004) (17)
- Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). (2018) (17)
- Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia (2022) (17)
- BTK C 481 S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia (2017) (17)
- A Phase I/II Study of Etanercept and Rituximab in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (2009) (17)
- Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach (2012) (17)
- Use of PD‐1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre (2018) (17)
- Outcomes with ibrutinib by line of therapy in patients with CLL: Analyses from phase III data. (2016) (17)
- Proteomic profiling identifies specific histone species associated with leukemic and cancer cells (2015) (17)
- Management of CLL patients early in the COVID‐19 pandemic: An international survey of CLL experts (2020) (17)
- Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies (2021) (17)
- MuCor: mutation aggregation and correlation (2015) (17)
- Low-cost, simple, and scalable self-assembly of DNA origami nanostructures (2019) (17)
- INTEGRATED ANALYSIS: OUTCOMES OF IBRUTINIB‐TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL) WITH HIGH‐RISK PROGNOSTIC FACTORS (2017) (17)
- Pattern of Use of Anticoagulation and/or Antiplatelet Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ibrutinib Therapy (2014) (17)
- Differential Role for Cyclic AMP Response Element Binding Protein-1 in Multiple Stages of B Cell Development, Differentiation, and Survival1 (2006) (16)
- Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation. (2003) (16)
- Enasidenib Is Highly Active in Previously Untreated IDH2 Mutant AML: Early Results from the Beat AML Master Trial (2018) (16)
- Cell surface complement inhibitors cd55 and cd59 may mediate chronic lymphocytic leukemia (cll) resistance to rituximab therapy (2000) (16)
- Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia. (2006) (16)
- Leukemic B Cell CTLA-4 Suppresses Costimulation of T Cells (2019) (16)
- DNA Origami Nanostructures Elicit Dose-Dependent Immunogenicity and Are Nontoxic up to High Doses In Vivo. (2022) (16)
- Mixed-Type Autoimmune Hemolytic Anemia following Fludarabine Treatment in a Patient with Chronic Lymphocytic Leukemia/Small Cell Lymphoma (1998) (16)
- Interplay of RUNX 1 / MTG 8 and DNA Methyltransferase 1 in Acute Myeloid Leukemia (2005) (16)
- Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110δ (PI3Kδ), in patients with relapsed or refractory mantle cell lymphoma (MCL). (2013) (16)
- Flavopiridol (Alvocidib) Induces Durable Responses in Relapsed Chronic Lymphocytic Leukemia (CLL) Patients with High-Risk Cytogenetic Abnormalities (2008) (16)
- A randomized, multicenter, open-label, phase III study of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) versus ofatumumab in patients (pts) with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): RESONATE. (2013) (16)
- Modulation of immune checkpoint molecule expression in mantle cell lymphoma (2019) (16)
- Combination Biologic Therapy as Initial Treatment for Follicular Lymphoma: Initial Results From CALGB 50701 - a Phase II Trial of Extended Induction Epratuzumab (anti-CD22) and Rituximab (anti-CD20) (2010) (16)
- In Vivo Quantification of Active Decitabine-Triphosphate Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (2012) (16)
- A Phase 1 Trial of TRU-016, An Anti-CD37 Small Modular Immunopharmaceutical (SMIPTM) Protein in Relapsed and Refractory CLL: Early Promising Clinical Activity. (2009) (16)
- Final results of a phase I study of idelalisib, a selective inhibitor of PI3Kδ, in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL). (2013) (16)
- Targeting Interleukin-2-Inducible T-cell Kinase (ITK) in T-Cell Related Diseases. (2014) (15)
- Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study (2012) (15)
- Abstract 1207: SNS-062 demonstrates efficacy in chronic lymphocytic leukemiain vitroand inhibits C481S mutated Bruton tyrosine kinase (2017) (15)
- Acalabrutinib, a second-generation bruton tyrosine kinase (Btk) inhibitor, in previously untreated chronic lymphocytic leukemia (CLL). (2016) (15)
- Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403 (2020) (15)
- Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease (2010) (15)
- Assaying pharmacodynamic endpoints with targeted therapy: Flavopiridol and 17AAG induced dephosphorylation of histone H1.5 in acute myeloid leukemia (2010) (15)
- A phase 1 / 1 b study of rituximab , bendamustine , and ibrutinib in patients with untreated and relapsed / refractory non-Hodgkin lymphoma (2014) (15)
- Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule. (2008) (15)
- Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Elevate-TN four-year follow up. (2021) (15)
- A phase I trial of TRU-016, an anti-CD37 small modular immunopharmaceutical (SMIP) in relapsed and refractory CLL. (2009) (15)
- Antibody therapy for chronic lymphocytic leukemia: a promising new modality. (2004) (15)
- ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo. (2015) (15)
- miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib. (2014) (15)
- Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2018) (15)
- Mutations associated with a 17-gene leukemia stem cell score and the score’s prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia (2019) (15)
- Interim Results of a Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia (2016) (14)
- Treatment with Fludarabine and Rituximab Produces Extended Overall Survival (OS) and Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) without Increased Risk of Second Malignancy: Long-Term Follow up of CALGB Study 9712. (2009) (14)
- Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma (2019) (14)
- Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia (2021) (14)
- Prolonged follow‐up after initial therapy with 2‐chlorodeoxyadenosine in patients with indolent non‐Hodgkin lymphoma (2006) (14)
- Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients (2021) (14)
- Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2 (2016) (14)
- The Bruton's Tyrosine Kinase (BTK) Inhibitor ARQ 531 Effectively Inhibits Wild Type and C481S Mutant BTK and Is Superior to Ibrutinib in a Mouse Model of Chronic Lymphocytic Leukemia (2016) (14)
- Autoimmune Hemolytic Anemia and Immune Mediated Thrombocytopenia in the Phase III RESONATETM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Including a Case Report (2014) (14)
- Acalabrutinib in treatment-naïve chronic lymphocytic leukemia: Mature results from phase II study demonstrating durable remissions and long-term tolerability. (2020) (14)
- Pharmacologically derived schedule of flavopiridol has significant efficacy in refractory, genetically high risk chronic lymphocytic leukemia (CLL). (2006) (14)
- A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma (2016) (14)
- Phase 1 Dose Escalation Study of TRU-016, An Anti-CD37 SMIP™ Protein In Relapsed and Refractory CLL (2010) (14)
- Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration (2020) (14)
- Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib (2018) (14)
- Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study. (2017) (14)
- Concurrent pernicious anemia and myelodysplastic syndrome (2001) (14)
- Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance) (2016) (13)
- Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA (2018) (13)
- The impact of increasing karyotypic complexity and evolution on survival in CLL patients treated with ibrutinib. (2021) (13)
- Statement from the Consensus Conference on Anti-D Prophylaxis (1998) (13)
- Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia. (2018) (13)
- Acalabrutinib with Obinutuzumab in Relapsed/Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia: The Phase 1b/2 ACE-CL-003 Study (2017) (13)
- A Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma (2014) (13)
- Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists. (2020) (13)
- Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B‐cell receptor pathway inhibitor (2018) (13)
- Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice (2021) (13)
- Improving the treatment outcome of patients with chronic lymphocytic leukemia through targeted antibody therapy. (2013) (13)
- Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Have Undergone Prior Allogeneic Stem Cell Transplant (2014) (13)
- Isolation and analysis of linker histones across cellular compartments. (2013) (13)
- MICA-Expressing Monocytes Enhance Natural Killer Cell Fc Receptor-Mediated Antitumor Functions (2017) (13)
- Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study. (2021) (13)
- Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia (2020) (13)
- Longitudinal Genome Wide Analysis of Patients with Chronic Lymphocytic Leukemia Reveals Complex Evolution of Clonal Architecture At Disease Progression and At the Time of Relapse (2011) (13)
- Risk Factors for Tumor Lysis Syndrome (TLS) In Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol. (2010) (13)
- A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485 (2017) (13)
- Lumiliximab in combination with FCR for the treatment of relapsed chronic lymphocytic leukemia (CLL): results from a phase I/II multicenter study (2008) (13)
- Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells (2016) (13)
- Initial Report of the Beat AML Umbrella Study for Previously Untreated AML: Evidence of Feasibility and Early Success in Molecularly Driven Phase 1 and 2 Studies (2018) (12)
- Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia. (2000) (12)
- Novel SF3B1 in-frame deletions result in aberrant RNA splicing in CLL patients. (2017) (12)
- Activation of the Intracellular Pattern Recognition Receptor NOD2 Promotes Acute Myeloid Leukemia (AML) Cell Apoptosis and Provides a Survival Advantage in an Animal Model of AML (2020) (12)
- High‐sensitivity TFA‐free LC‐MS for profiling histones (2011) (12)
- The regulation of tumor‐suppressive microRNA, miR‐126, in chronic lymphocytic leukemia (2017) (12)
- Advances in the therapy of chronic lymphocytic leukemia. (2003) (12)
- Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia. (2021) (12)
- G3139, a BCL-2 antisense oligo-nucleotide, in AML. (2004) (12)
- A Single-Institution Retrospective Cohort Study of Patients Treated with R-EPOCH for Richter's Transformation of Chronic Lymphocytic Leukemia (2015) (12)
- Novel presentation of acute myelogenous leukemia as symptomatic galactorrhea. (2001) (12)
- Abstract 1744: ACP-196: A second generation Btk inhibitor demonstrates biologic activity in a canine model of B-cell non-Hodgkin lymphoma (2014) (12)
- Novel therapies and their integration into allogeneic stem cell transplant for chronic lymphocytic leukemia. (2012) (12)
- Interferon-γ Promotes Antibody-mediated Fratricide of Acute Myeloid Leukemia Cells* (2016) (12)
- Diffuse alveolar hemorrhage following gemtuzumab ozogamicin (2005) (12)
- A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia (2019) (12)
- Antibody therapy in chronic lymphocytic leukemia. (2003) (12)
- A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with heavily pretreated non-Hodgkin lymphoma (NHL). (2014) (11)
- The impact of inflammation-induced tumor plasticity during myeloid transformation. (2022) (11)
- Pharmacodynamic Evaluation of Acalabrutinib in Relapsed/Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia (CLL) in the Phase 1/2 ACE-CL-001 Study (2017) (11)
- Low levels of miR-92 b / 96 induce PRMT 5 translation and H 3 R 8 / H 4 R 3 methylation in mantle cell lymphoma (2013) (11)
- Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL. (2011) (11)
- A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors (2010) (11)
- Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia (2020) (11)
- Induction of T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo (2003) (11)
- Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia. (2020) (11)
- Introduction to a series of reviews on chronic lymphocytic leukemia. (2015) (11)
- Acute pancreatitis associated with continuous infusion cytarabine therapy: A case report (1996) (11)
- Translating PI3K-Delta Inhibitors to the Clinic in Chronic Lymphocytic Leukemia: The Story of CAL-101 (GS1101). (2012) (11)
- A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia (2016) (11)
- Ibrutinib (PCI-32765) Antagonizes Rituximab-Dependent NK-Cell Mediated Cytotoxicity (2013) (11)
- FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R]. (2008) (11)
- XmAb-5574 antibody demonstrates superior antibody-dependent cellular cytotoxicity as compared with CD52- and CD20-targeted antibodies in adult acute lymphoblastic leukemia cells (2012) (11)
- Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia (2009) (11)
- the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL (2016) (11)
- PrEMeR-CG: inferring nucleotide level DNA methylation values from MethylCap-seq data (2014) (11)
- CLEAR: coverage-based limiting-cell experiment analysis for RNA-seq (2018) (11)
- Evaluation of the novel Bruton′s tyrosine kinase (BTK) inhibitor GDC-0853 in chronic lymphocytic leukemia (CLL) with wild type or C481S mutated BTK. (2016) (11)
- A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia. (2014) (11)
- 11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies (2016) (11)
- Fcγ Receptor-induced Soluble Vascular Endothelial Growth Factor Receptor-1 (VEGFR-1) Production Inhibits Angiogenesis and Enhances Efficacy of Anti-tumor Antibodies* (2013) (11)
- Ventricular Arrhythmias and Sudden Death Events following Acalabrutinib initiation. (2022) (11)
- Efficacy and safety of recombinant interleukin-21 (rIL-21) and rituximab in relapsed/refractory indolent lymphoma (2008) (11)
- Activation of PP2A by FTY720 Inhibits Survival and Self-Renewal of the Ph(+) Chronic Myelogenous Leukemia (CML) CD34 + /CD38 − Stem Cell through the Simultaneous Suppression of BCR/ABL and BCR/ABL– independent Signals (2008) (11)
- Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy (2021) (11)
- Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma (2015) (11)
- Cancer-Specific Stress and Trajectories of Psychological and Physical Functioning in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia. (2018) (11)
- Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia (2020) (11)
- Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma (2009) (11)
- A Novel Celecoxib Derivative , OSU 03012 , Induces Cytotoxicity in Primary CLL Cells and Transformed B-cell Lymphoma via a Caspase and Bcl-2 Independent Mechanism (2004) (11)
- A phase 1b/2 study evaluating activity and tolerability of the BTK inhibitor ibrutinib in combination with ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. (2014) (11)
- Early Evidence of Anti-Lymphoma Activity of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Heavily Pre-Treated Low Grade Lymphoma and Diffuse Large Cell Lymphoma Patients (2010) (11)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- Phase 1 Trial of Flavopiridol and Lenalidomide In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL) (2010) (10)
- Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Results From the Randomized Phase III RESONATE™ (PCYC-1112) Trial (2015) (10)
- Cyclophosphamide Remains An Important Component of Treatment in CLL Patients Receiving Pentostatin and Rituximab Based Chemoimmunotherapy (2008) (10)
- Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin's Lymphoma (2021) (10)
- Proposal for a Soft X-ray Diffraction Limited Upgrade of the ALS (2014) (10)
- Phase II trial of temsirolimus (CCI-779) in patients with relapsed or refractory multiple myeloma (MM): Preliminary results. (2006) (10)
- The phosphatidylinositol 3-kinase-δ Inhibitor CAL-101 demonstrates promising pre-clinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals (2010) (10)
- A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin’s lymphoma (2006) (10)
- Major Bleeding Complications Among Patients Treated with Ibrutinib and Concomitant Antiplatelet, Anticoagulant, or Supplemental Therapy (2016) (10)
- Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997 (2015) (9)
- Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition (2021) (9)
- Early clinical activity and pharmacodynamic effects of duvelisib, a PI3K-δ,γ inhibitor, in patients with treatment-naïve CLL. (2015) (9)
- Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). (2021) (9)
- Human herpesvirus 8 genome is not found in whole bone marrow core biopsy specimens of patients with plasma cell dyscrasias (2002) (9)
- Campath-1 H monoclonal antibody therapy (9)
- ALPINE: Phase III zanubrutinib (BGB-3111) versus ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). (2019) (9)
- The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia (2015) (9)
- TRU-016, An Anti-CD37 SMIP™ Biologic, In Combination with Other Therapeutic Drugs In Models of Non-Hodgkin's Lymphoma (2010) (9)
- Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective (2015) (9)
- Lumiliximab with fludarabine, cyclophosphamide, and rituximab (FCR) for patients with relapsed chronic lymphocytic leukemia (CLL). (2006) (9)
- The Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Monotherapy Demonstrates Long-Term Safety and Durability Of Response In Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients In An Open-Label Extension Study (2013) (9)
- Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib (2019) (9)
- All B cells are not the same: a story of CD40 activation (2004) (9)
- Challenges and approaches to implementing master/basket trials in oncology. (2019) (9)
- International Standardized Approach to Molecular and Flow Cytometric Residual Disease Monitoring in CLL. (2004) (9)
- NF-κB p50 (nfkb1) contributes to pathogenesis in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia. (2017) (9)
- Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL (2020) (9)
- Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies (2013) (9)
- Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT 3‐ITD AML (2019) (9)
- Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies (2019) (9)
- Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia (2016) (9)
- PLK1: a promising and previously unexplored target in double-hit lymphoma. (2018) (9)
- Carboxyamido-Triazole (CAI)-a Novel “static” Signal Transduction Inhibitor Induces Apoptosis in Human B-Cell Chronic Lymphocytic Leukemia Cells (2001) (9)
- Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (2016) (8)
- Preliminary Results of a Phase II Study of Low Dose Decitabine as a Single Agent in Older Patients (age≥60) with Previously Untreated Acute Myeloid Leukemia (AML) (2008) (8)
- Phase 1 study of selinexor plus mitoxantrone, etoposide, and cytarabine in acute myeloid leukemia. (2018) (8)
- Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001) (2015) (8)
- The Bruton Tyrosine Kinase (Btk) Inhibitor ACP-196: Marked Activity in Relapsed/Refractory CLL with a Favorable Safety Profile (2015) (8)
- Safety of acalabrutinib (Acala) monotherapy in hematologic malignancies: Pooled analysis from clinical trials. (2020) (8)
- Assessment of Promoter Methylation Identifies PTCH as a Putative Tumor-suppressor Gene in Human CLL. (2016) (8)
- THE INTERNATIONAL PROGNOSTIC INDEX FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL-IPI)-AN INTERNATIONAL META-ANALYSIS (2015) (8)
- Phase 1 Study of Tru-016, An Anti-CD37 SMIP™ Protein in Naïve and Relapsed and/or Refractory CLL Patients (2011) (8)
- Activity of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed, genetically high risk chronic lymphocytic leukemia (CLL) (2008) (8)
- Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3) (2016) (8)
- Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single‐agent ibrutinib in patients with chronic lymphocytic leukaemia (2019) (8)
- LONG‐TERM EFFICACY AND SAFETY IN THE RESONATE STUDY: IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH UP TO FOUR YEARS FOLLOW‐UP (2017) (8)
- Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. (2012) (8)
- CAL-101, An Oral p110δ Selective Phosphatidylinositol-3-Kinase (PI3K) Inhibitor for the Treatment of B Cell Malignancies Inhibits PI3K Signaling, Cellular Viability and Protective Signals of the Microenvironment. (2009) (8)
- Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia (2020) (8)
- X-ray streak camera temporal resolution improvement using a longitudinal time-dependent field (2008) (8)
- Alemtuzumab Induces Cell Death in Human Chronic Lymphocytic Leukemia Cells through a Lipid Raft-Dependent Mechanism. (2004) (8)
- Targeting PI3Kδ function for amelioration of murine chronic graft‐versus‐host disease (2019) (8)
- TP-0903 is active in models of drug-resistant acute myeloid leukemia (2020) (8)
- Outcome of Treatment with Fludarabine Versus Fludarabine and Cyclophosphamide in Chronic Lymphocytic Leukemia (CLL) Is Adversely Impacted by High Risk Genetic Features: Results from ECOG 2997. (2004) (8)
- CpG oligodeoxynucleotide CpG-685 upregulates functional interleukin-21 receptor on chronic lymphocytic leukemia B cells through an NF-κB mediated pathway (2015) (8)
- Identifying risk factors for depression and anxiety symptoms in patients with chronic lymphocytic leukemia (2019) (8)
- Jumping translocations, a novel finding in chronic lymphocytic leukaemia (2015) (8)
- DNA Origami: Daunorubicin-Loaded DNA Origami Nanostructures Circumvent Drug-Resistance Mechanisms in a Leukemia Model (Small 3/2016). (2016) (8)
- Acalabrutinib with obinutuzumab (Ob) in treatment-naive (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Three-year follow-up. (2019) (8)
- Hematologic improvement after flavopiridol treatment of pentostatin and rituximab refractory hairy cell leukemia (2012) (8)
- Chronic lymphocytic leukemia with del(17p13.1): a distinct clinical subtype requiring novel treatment approaches. (2012) (8)
- Combination anti-CD 74 ( milatuzumab ) and anti-CD 20 ( rituximab ) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma (2011) (8)
- Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia (2019) (8)
- Flavopiridol given as a 30-min intravenous (IV) bolus followed by 4-hr continuous IV infusion (CIVI) results in clinical activity and tumor lysis in refractory chronic lymphocytic leukemia (CLL). (2004) (8)
- Liposomal Targeted Delivery Overcomes Immunostimulatory Effects of Oligonucleotide Based Therapy In Chronic Lymphocytic Leukemia. (2010) (8)
- Have we forgotten the purpose of phase III studies? (2007) (8)
- Gene Dosage of the Cell Cycle Regulatory Phosphatases Cdc25C and PP2A Determines Sensitivity to Lenalidomide in del(5q) MDS. (2007) (7)
- Phase I Study of Low Dose Decitabine in Patients with Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity. (2005) (7)
- A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities. (2006) (7)
- Subcutaneous Injections of IMMU-114 (Anti-HLA-DR IgG4 Monoclonal Antibody): Initial Results of a Phase I First-in-Man Study in Hematologic Malignancies (2015) (7)
- Auranofin Induces a Reversible In-Vivo Stress Response That Correlates With a Transient Clinical Effect In Patients With Chronic Lymphocytic Leukemia (2013) (7)
- Dinaciclib (SCH727965) Is a Novel Cyclin Dependent Kinase Inhibitor That Promotes Selective Apoptosis In CLL Cells and Abrogates the Protective Effects of Microenvironment Cytokines (2010) (7)
- Identification of Endoplasmic Reticulum Stress Inducing Agents by Antagonizing Autophagy: A New Potential Strategy for Identification of Anti-Cancer Therapeutics in B-Cell Malignancies. (2012) (7)
- Flavopiridol Is Active in Genetically High-Risk, Relapsed Chronic Lymphocytic Leukemia (CLL): Analysis of 56 Patients by Cytogenetic Abnormality. (2006) (7)
- Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101 (2013) (7)
- Phase 1b Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIRTM Protein, in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia (CLL) (2014) (7)
- Final Results and Follow-up of a Phase I Study of the Fc Engineered CD19 Antibody XmAb®5574 (aka MOR00208) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (2012) (7)
- Recombinant Interleukin-21 Plus Rituximab: Clinical Activity in a Phase 1, Dose-Finding Trial in Relapsed Low-Grade B Cell Lymphoma. (2007) (7)
- DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia (2021) (7)
- BRAFV600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation. (2015) (7)
- Resistance to Bruton's Tyrosine Kinase Inhibitors: The Achilles Heel of Their Success Story in Lymphoid Malignancies. (2021) (7)
- CD37−SMIPTM Drug Induced Caspase Independent Cellular Cytotoxicity Is Associated with Activation of Phosphotyrosine-Mediated Signaling Events in Primary Chronic Lymphocytic Leukemia (CLL) B Cells. (2006) (7)
- Precision Medicine Treatment in Older AML: Results of Beat AML Master Trial (2019) (7)
- Clinical roundtable monograph: unmet needs in the treatment of chronic lymphocytic leukemia: integrating a targeted approach. (2014) (7)
- Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. (2018) (7)
- Dinaciclib (SCH 727965) and Ofatumumab for the Treatment of Relapsed and Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): Results of a Phase 1b/2 Study (2014) (7)
- Updated Results of a Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma (2015) (7)
- FTY 720 increases CD 74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death (2011) (7)
- NK Cells Contribute Significantly to the Innate Immune Effector Role of CD37-Specific SMIP in CLL and NHL. (2006) (7)
- Humanized Anti CD-40 Antibody SGN-40 Effectively Induces Cytotoxicity Against Chronic Lymphocytic Leukemia (CLL) Cells through Antibody Mediated Cytotoxicity and Demonstrates Modest Biologic Evidence of CD40 Activation. (2005) (6)
- Leukemic thyroiditis as the initial relapsing sign in a patient with acute lymphocytic leukemia and blast expression of the neural cell adhesion molecule (1997) (6)
- Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia (2020) (6)
- Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement (2021) (6)
- FIRST RESULTS OF A HEAD‐TO‐HEAD TRIAL OF ACALABRUTINIB VERSUS IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (2021) (6)
- A Phase 1 Dose Escalation Study of ARQ 531 in Selected Patients with Relapsed or Refractory Hematologic Malignancies (2018) (6)
- Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism (2016) (6)
- A Phase 1 Clinical Trial of Selinexor in Combination with Decitabine in Patients with Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia (2016) (6)
- Combination Bortezomib (PS341, Velcade) and Rituximab Treatment Affects Multiple Survival and Death Pathways To Promote Apoptosis in Mantle Cell Lymphoma. (2005) (6)
- Flavopiridol, Fludarabine and Rituximab Is a Highly Active Regimen in Indolent B-Cell Lymphoproliferative Disorders Including Mantle Cell Lymphoma. (2005) (6)
- Antibody therapy of acute and chronic leukemias. (2001) (6)
- Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL (2021) (6)
- Rarity of B-Cell Receptor Pathway Mutations in Progression-Free Patients With Chronic Lymphocytic Leukemia (CLL) During First-Line Versus Relapsed/Refractory (R/R) Treatment With Ibrutinib (2020) (6)
- The Cyclin Dependent Kinase Inhibitor SCH 727965 Demonstrates Promising Pre-Clinical and Early Clinical Activity in Chronic Lymphocytic Leukemia. (2009) (6)
- Phase I trial of bortezomib in combination with paclitaxel in advanced solid tumor patients (pts) (2005) (6)
- Phase I Study of Low-Dose Interleukin-2, Fludarabine, and Cyclophosphamide for Previously Untreated Indolent Lymphoma and Chronic Lymphocytic Leukemia (2005) (6)
- Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies (2011) (6)
- PS1150 A PHASE 1 DOSE ESCALATION STUDY OF ARQ 531 IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL LYMPHOID MALIGNANCIES (2019) (6)
- Dose adherence and baseline exposure analysis of the ibrutinib 420 mg dose administered to patients with previously treated chronic lymphocytic leukemia (CLL). (2015) (6)
- Investigating the Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy: Results from a Phase Ib Study (2021) (6)
- Community-based phase II trial of PCR for CLL/SLL patients. (2007) (6)
- Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): 8 Year Follow up of CALGB 50403 (Alliance) (2018) (6)
- Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling. (2019) (6)
- PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia (2021) (6)
- Bexarotene-Induced T-Cell Immunomodulation and Response in CTCL. (2004) (6)
- An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia (2022) (6)
- Clonal lymphocytosis of uncertain significance (CLUS): what clues will CLUS yield? (2002) (6)
- Poor Treatment Outcomes of Young (<60 Years) African American Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance) (2020) (5)
- Characterization and mitigation of fragmentation enzyme-induced dual stranded artifacts (2020) (5)
- Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia (2020) (5)
- Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611). (2018) (5)
- Phase II study of the histone deacetylase inhibitor MGCD 0103 in patients with previously treated chronic lymphocytic leukaemia (2009) (5)
- Identification of clinically distinct types of diffuse large B-cell lymphoma based on gene expressio (2000) (5)
- LC-FACSeq is a method for detecting rare clones in leukemia. (2020) (5)
- CAL-101, a Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3-Kinase, Effectively Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells Providing a Novel Therapeutic Strategy for the Treatment of This Disease (2008) (5)
- Imaging intercellular interaction and extracellular vesicle exchange in a co-culture model of chronic lymphocytic leukemia and stromal cells by lattice light-sheet fluorescence microscopy. (2020) (5)
- CAL-101, a Potent Selective Inhibitor of the p110d Isoform of Phosphatidylinositol 3-Kinase, Attenuates PI3K Signaling and Inhibits Proliferation and Survival of Acute Lympoblastic Leukemia in Addition to a Range of Other Hematological Malignancies (2008) (5)
- A Phase II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin’s Lymphoma (2008) (5)
- Gemcitabine demonstrates in vitro activity against human B-cell chronic lymphocytic leukemia. (2001) (5)
- IL-21 Mediates Apoptosis Through Up-Regulation of the BH3 Family Member BIM and Enhances both Direct and Antibody Dependent Cellular Cytotoxicity in Primary Chronic Lymphocytic Cells (2007) (5)
- Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202 (2021) (5)
- Immuno-Chemotherapy (IC) and Autologous Stem Cell Transplant (ASCT) for Untreated Patients (pts) with Mantle Cell Lymphoma (MCL): CALGB 59909. (2006) (5)
- Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia (2019) (5)
- HSP90 inhibition without heat shock response. (2018) (5)
- Clinical Activity of Flavopiridol in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) with High-Risk Cytogenetic Abnormalities: Updated Data on 89 Patients (Pts). (2007) (5)
- Erratum: A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide (Proceedings of the National Academy of Sciences of the United States of America (2009) 106:31 (12974-12979) DOI: 10.1073/pnas.0811267106) (2013) (5)
- Chronic Lymphocytic Leukemia Patients with IGHV Genes Carrying Only Silent Mutations Have A Longer Time From Diagnosis to Initial Therapy Than Patients Expressing B-Cell Receptors with No Somatic Mutations (2011) (5)
- Correction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation (2017) (5)
- Antagonizing ClpP: A New Power Play in Targeted Therapy for AML. (2015) (5)
- Mass Cytometry: A High-Throughput Platform to Visualize the Heterogeneity of Acute Myeloid Leukemia. (2015) (5)
- Molecular Complete Remission Following Ivosidenib in a Patient With an Acute Undifferentiated Leukemia. (2020) (5)
- Phase 2 Study of Three Doses of Single Agent Bortezomib in Patients with Fludarabine-Refractory B-Cell CLL. (2004) (5)
- FTY 720 Induces Apoptosis in Hepatocellular Carcinoma Cells through Activation of Protein Kinase C D Signaling (2008) (5)
- Quantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography-tandem mass spectrometry. (2014) (5)
- Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia (2014) (5)
- Loss of expression of both miR-15/16 loci in CML transition to blast crisis (2021) (5)
- Spotlight on Ibrutinib in PCNSL: Adding Another Feather to Its Cap. (2017) (5)
- Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma. (2017) (5)
- Outcomes of Ibrutinib Therapy By Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2) (2016) (5)
- Population pharmacokinetics of lenalidomide in patients with B‐cell malignancies (2019) (5)
- Flavopiridol Can Be Safely Dose Escalated in Relapsed CLL Patients: Achievement of Target C max Results in Improved Clinical Activity. (2006) (5)
- Effect of CD37 small modular immuno-pharmaceutical (SMIP) on direct apoptosis in chronic lymphocytic leukemia cells via transcriptional up-regulation of the BH3 family member BIM. (2009) (5)
- Immunoliposomes Incorporated with Humanized Monoclonal Antibody, Milatuzumab, Induce Cell Death in CLL by Retention of the CD74 Receptor On the Surface of B Cells. (2009) (5)
- Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma. (2012) (5)
- IRF4(-/-)Vh11 mice: a novel mouse model of CLL. (2013) (5)
- Phase 1b Dose Escalation Study of BI 836858 and Azacitidine in Previously Untreated AML: Results from Beat AML S2 (2018) (5)
- Preliminary Results of a Phase I Study of Lenalidomide in Relapsed Chronic Lymphocytic Leukemia. (2009) (5)
- Venetoclax Adds a New Arrow Targeting Relapsed CLL to the Quiver. (2016) (4)
- A Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase (RNR) in Combination with High-Dose Cytarabine (HiDAC) in Relapsed or Refractory Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamic (PD) and Clinical Results. (2005) (4)
- P06.01A DOSE ESCALATION STUDY OF IBRUTINIB WITH LENALIDOMIDE FOR RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (2013) (4)
- Low Incidence of Opportunistic Infections in CLL Patients Treated with Single Agent Flavopiridol. (2007) (4)
- Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21 (2019) (4)
- Pooled Analysis of Cardiovascular Events from Clinical Trials Evaluating Acalabrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia (CLL) (2020) (4)
- Introduction: chronic lymphocytic leukemia. (1998) (4)
- Prognostic Significance Of Cytogenetic Complexity and Del(17p) At Diagnosis Of Chronic Lymphocytic Leukemia (CLL) (2013) (4)
- Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL (2019) (4)
- Depth of response and progression free survival in CLL patients on ibrutinib. (2018) (4)
- Synergistic Interactions between Imatinib and the Novel Phosphoinositide-Dependent Kinase-1 Inhibitor OSU-03012 in Overcoming Imatinib Resistance Running title : Overcome imatinib resistance by a PDK-1 inhibitor (2005) (4)
- Flavopiridol in Chronic Lymphocytic Leukemia (2007) (4)
- Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (2019) (4)
- BRAFV600E Induces ABCB1/P-Glycoprotein Expression and Drug Resistance in B-Cells Via AP-1 Activation (2015) (4)
- Effects of the Redox Mediator Motexafin Gadolinium in a Pilot Phase I Trial in Refractory Chronic Lymphocytic Leukemia (CLL). (2004) (4)
- Phase 1b Study of TRU-016, an Anti-CD37 SMIP™ Protein, in Combination with Bendamustine Vs Bendamustine Alone in Relapsed Chronic Lymphocytic Leukemia (2012) (4)
- CLL and activated NF-kappaB: living partnership. (2008) (4)
- The Eµ-Myc/TCL1 Transgenic Mouse As a New Aggressive B-Cell Malignancy Model Suitable for Preclinical Therapeutics Testing (2015) (4)
- BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia (2014) (4)
- BRAF V600E accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia (2017) (4)
- Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL (2020) (4)
- Flavopiridol Is An Effective Therapy to Bridge Patients with Chronic Lymphocytic Leukemia (CLL) to Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant (2010) (4)
- Chronic lymphocytic leukemia: recent progress and current challenges. (2016) (4)
- Hypermorphic mutation of phospholipase C, gamma 2 acquired in ibrutinib resistant CLL confers BTK independency upon BCR activation (2015) (4)
- Inhibitors of Bruton's Tyrosine Kinase Reduce Anti-Red Blood Cell Response in a Murine Model of Autoimmune Hemolytic Anemia (2016) (4)
- BRAFV600E accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia. (2016) (4)
- OSU‐DY7, a novel D‐tyrosinol derivative, mediates cytotoxicity in chronic lymphocytic leukaemia and Burkitt lymphoma through p38 mitogen‐activated protein kinase pathway (2011) (4)
- Gly101Val BCL2 Mutation: One Step Closer to Understanding Venetoclax Resistance in CLL. (2019) (4)
- Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL) (2019) (4)
- ZUMA-8: A phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). (2019) (4)
- Response, Progression-Free Survival, and Overall Survival of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor Risk Cytogenetic Abnormalities (2010) (4)
- Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR). (2007) (4)
- Select High Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy with Fludarabine and Rituximab in Chronic Lymphocytic Leukemia (CLL): Preliminary Justification for Risk-Adapted Therapy. (2004) (4)
- High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML (2022) (4)
- Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study (2019) (4)
- Increased Incidence of Therapy Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) Vs Fludarabine (F): Long-Term Follow-up of US Intergroup Study E2997 (2010) (4)
- The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia. (2021) (4)
- The Kinase Inhibitor, PCI-32765, Demonstrates Activity In Chronic Lymphocytic Leukemia Cells Independent of Microenvironmental Survival Signals (2010) (4)
- The Novel BET Inhibitor PLX51107 Has In Vitro and In Vivo Activity Against Acute Myeloid Leukemia (2016) (4)
- Ibrutinib Treatment Reduces Both T-Regulatory Cells and B-Regulatory Cell Phenotype in Malignant B Cells in Chronic Lymphocytic Leukemia Patients (2015) (4)
- Phase I trial of subcutaneous (SQ) alemtuzumab (A) and CHOP in T-cell lymphoma: Preliminary results. (2006) (4)
- HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics (2019) (4)
- Anti-tumor NAMPT inhibitor, KPT-9274, mediates gender-dependent murine anemia and nephrotoxicity by regulating SIRT3-mediated SOD deacetylation (2021) (4)
- Novel Anti-CD37 Small Modular Immunopharmaceutical (SMIP) Induces B-Cell-Specific, Caspase-Independent Apoptosis in Human CLL Cells. (2004) (4)
- Activity of Combined Flavopiridol and Lenalidomide in Patients with Cytogenetically High Risk Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase I Trial, (2011) (4)
- Final Results of a Dose Escalation Study of Flavopiridol in Acute Leukemias Using a Novel Treatment Schedule. (2007) (4)
- Cancer Therapy : Preclinical Targeted Delivery of microRNA-29 b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles : A Novel Therapeutic Strategy in Acute Myeloid Leukemia (2013) (4)
- Idelalisib monotherapy and durable responses in patients with relapsed or refractory Waldenstroms Macroglobulinemia (WM). (2015) (4)
- Comparative Evaluation of Prognostic Factors That Assess the Natural History of Chronic Lymphocytic Leukemia (2016) (4)
- Incidence of Autoimmune Cytopenias (AIC) in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) Patients (pts) Treated with Ibrutinib (2014) (4)
- Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes (2022) (4)
- Flavopiridol, fludarabine and rituximab (FFR) is an active regimen in indolent B-cell lymphoproliferative disorders and mantle cell lymphoma (MCL). (2006) (4)
- Whole-genome sequencing for myeloid disease: one assay to stratify them all? (2021) (3)
- Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation (2022) (3)
- Changes in clinical stage identify patients with CLL and different outcome within iwCLL partial response: RESONATE study (2018) (3)
- Acute Pancreatitis Associated with Continuous Infusion Cytarabine Therapy (1996) (3)
- Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia (2020) (3)
- CRM1/XPO1 Represents a Promising Therapeutic Target for Treatment of Chronic Lymphocytic Leukemia (2011) (3)
- Monoclonal antibody therapy for hematologic malignancies: Introduction* (2003) (3)
- Therapeutic Targeting of B-Cell Receptor Signaling Pathways (2012) (3)
- Kinetic Measurement of Leukemia-Cell Proliferation Rate By Deuterium Labeling Predicts Time to Initial Treatment of Patients with Chronic Lymphocytic Leukemia (2014) (3)
- Folate Receptor-Targeted Liposomes for Cancer Therapy (2006) (3)
- Mitochondrial Priming of Chronic Lymphocytic Leukemia Patients Associates Bcl-xL Dependence with Alvocidib Response (2014) (3)
- Optimizing extracellular vesicles’ isolation from chronic lymphocytic leukemia patient plasma and cell line supernatant (2021) (3)
- The Aberrantly Expressed Long Noncoding RNA, TRERNA1, Predicts for Aggressive Disease in Chronic Lymphocytic Leukemia (2015) (3)
- A Phase I Trial of Subcutaneous (SQ) Dose-Escalated Alemtuzumab in Patients with T-Cell Lymphoproliferative Disorders (T-LPD). (2007) (3)
- Abstract CT158: Unmutated IGHV is not an adverse predictor of outcome to therapy with ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2017) (3)
- Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study (2022) (3)
- Phase Ib Study of Ianalumab (VAY736) and Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy (2020) (3)
- Relative Value of CD38 and ZAP-70 Versus Immunoglobulin Mutation Status in Predicting Early Disease Progression in Chronic Lymphocytic Leukemia. (2006) (3)
- Expression of PRMT5 in B-Cell Chronic Lymphocytic Leukemia and Its Significance in Disease Progression and Richter's Transformation (2014) (3)
- The TCL-1 Transgenic Mouse Is an Effective Tool for Pre-Clinical Drug Development in Chronic Lymphocytic Leukemia. (2005) (3)
- Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial (2019) (3)
- Outcomes of the cyclophosphamide, vincristine, prednisone (CVP) +/- rituximab (R-CVP) regimen in older patients with newly diagnosed Ph- acute lymphoblastic leukemia. (2020) (3)
- The plant-derived agent silvestrol has B-Cell selective activity in vitro in chronic lymphocytic leukemia patient cells and in vivo in the Tcl-1 mouse model of CLL (2007) (3)
- NK Cell–Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines (2016) (3)
- Evaluation of allogeneic and autologous membrane-bound IL-21–expanded NK cells for chronic lymphocytic leukemia therapy (2022) (3)
- Role of Mutant p53 in the Progression of Chronic Lymphocytic Leukemia (2019) (3)
- CD52 Expression in Adult Acute Lymphoblastic Leukemia (ALL): Quantitative Flow Cytometry Provides New Insights. (2006) (3)
- Aging Phenotypes and Restoring Functional Deficits in Older Adults With Hematologic Malignancy. (2021) (3)
- Monoclonal Antibody Therapy in Chronic Lymphocytic Leukemia (2004) (3)
- Selinexor combined with ibrutinib demonstrates tolerability and safety in advanced B-cell malignancies: A phase I study. (2022) (3)
- Monoclonal antibody therapy in lymphoid leukemias. (2004) (3)
- Activation of the FcgammaReceptorIIIa on human natural killer cells leads to increased expression of functional interleukin-21 receptor (2017) (3)
- What choices are available for treatment of the patient with chronic lymphocytic leukemia who is fludarabine-refractory? (2000) (3)
- A precision medicine classification for treatment of acute myeloid leukemia in older patients (2021) (3)
- Targeting CD20 takes the backseat in CLL. (2019) (3)
- Theophylline, pentostatin (Nipent), and chlorambucil: a dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders. (2000) (3)
- Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia (2020) (3)
- A Novel Regimen for Acute Myeloid Leukemia with MLL Partial Tandem Duplication: Results of a Phase 1 Study NCI 8485 (2016) (3)
- BAFF and related proteins: a new therapeutic target for B-cell malignancies (2004) (3)
- Barriers to Reduced-Intensity Conditioning (RIC) Transplant in Patients with Chronic Lymphocytic Leukemia. (2009) (3)
- A Phase I Trial of the Intravenous (IV) Hsp90 Inhibitor 17-DMAG (alvespimycin) in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (2012) (3)
- Basic References (3)
- Circulating Mir-16 and Mir-25 As New Prognosticators For Multiple Myeloma (2013) (3)
- Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition (2021) (3)
- A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL) (2015) (3)
- CD38 Compared with ZAP-70 or Immmunoglobulin Mutation Status as Predictor of Disease Progression in Chronic Lymphocytic Leukemia. (2004) (3)
- Abstract B19: Population pharmacokinetic-pharmacodynamic (PKPD) modeling of ibrutinib in patients with B-cell malignancies. (2015) (3)
- Evidence of MicroRNA-29b and Sp1/NFκB-HDAC Regulatory Network for KIT Expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications. (2009) (3)
- Hearing Loss due to Infiltration of the Tympanic Membrane by Chronic Lymphocytic Leukemia (2012) (3)
- Pharmacokinetics of Single-Agent Lumiliximab (Anti-CD23 Antibody) in Patients with Chronic Lymphocytic Leukemia. (2004) (3)
- Covariation of psychological and inflammatory variables in patients with chronic lymphocytic leukemia receiving ibrutinib. (2014) (3)
- NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma, Version 4.2020 (2020) (3)
- Clinical and Prognostic Implications of PTPN11 Mutations in Acute Myeloid Leukemia (Alliance) (2020) (3)
- HLA-DR meets ERK. (2010) (3)
- Phase I study of a novel, pharmacokinetically derived schedule of flavopiridol in acute leukemias: Clinical efficacy including hyperacute tumor lysis, pharmacokinetics, and pharmacodynamics. (2006) (3)
- A Phase 1b-2 Study of KRT-232, a First-in-Class, Oral, Small Molecule Inhibitor of Murine Double Minute 2 (MDM2), in Combination with Acalabrutinib for the Treatment of Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or R/R Diffuse Large B-Cell Lymphoma (DLBCL) (2020) (3)
- Targeting BTK By a microRNA Mechanism in Chronic Lymphocytic Leukemia (2015) (2)
- Treatment with Auranofin Induces Oxidative and Lethal Endoplasmic Reticulum (ER) Stress Exerting Single Agent Activity Against Primary CLL Cells (2011) (2)
- Alliance A041701 - a Randomized Phase 2/3 Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia (AML) Receiving Intensive Induction Chemotherapy (2019) (2)
- Phase I Dose Escalation Study of Flavopiridol in Combination with Fludarabine and Rituximab: Activity in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma. (2004) (2)
- Phase 1b Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIR™ Protein, In Combination With Rituximab In Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (2013) (2)
- Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial (2020) (2)
- Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib and acalabrutinib treated patients. (2022) (2)
- Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration (2018) (2)
- Abstract 1584: Targeting protein arginine methyltransferase 5 (PRMT5) enzyme over expression in high grade astrocytomas (2010) (2)
- 5.43 Patterns of Nodal Response and Lymphocytosis in Patients with Previously Treated CLL Receiving the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, CAL-101 (GS-1101) Alone or in Combination with Rituximab (R) or Bendamustine (B) (2011) (2)
- A Phase 2 Trial of Early Intervention with Ibrutinib in Patients with Asymptomatic, High-Risk CLL (2017) (2)
- Chapter 77 – Chronic Lymphocytic Leukemia (2018) (2)
- Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells (2012) (2)
- Erratum: Cholesterol as a bilayer anchor for PEGylation and targeting ligand in folate-receptor-targeted liposomes. J Pharm Sci 96: 2424-2435 (2010) (2)
- Tumor Antigen ROR1 Targeted Delivery of MiR-29b in Chronic Lymphocytic Leukemia Induces Epigenetic Reprograming Resulting in Cell Cycle Arrest (2017) (2)
- Durability of response to venetoclax (VEN) in patients with CLL relapsed/refractory to ibrutinib and/or idelalisib. (2018) (2)
- Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter’s transformation (2023) (2)
- Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity (2019) (2)
- FTY 720 Shows Promising In vitro and In vivo Preclinical Activity by Downmodulating Cyclin D 1 and Phospho-Akt in Mantle Cell Lymphoma (2010) (2)
- Hu 1 D 10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells (2004) (2)
- Durable complete response (CR) and suppression of the human T-cell leukemia virus (HTLV-1) viral load (VL) with alemtuzumab in refractory adult T-cell leukemia (ATL) (2005) (2)
- A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance). (2017) (2)
- A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary ef fi cacy in relapsed CLL (2014) (2)
- Complex Karyotype (CK) Is Associated with a Shortened Progression-Free Survival (PFS) in Patients (pts) with Newly Diagnosed Mantle Cell Lymphoma (MCL). (2012) (2)
- A Phase I Dose Escalation Study of Lenalidomide Following Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation (2014) (2)
- Non-Hodgkin’s Lymphomas, Version 4.2014: Clinical Practice Guidelines in Oncology (2014) (2)
- Abstract 4637: Evaluation of the pharmacokinetics and food effect of oral ibrutinib in healthy subjects and chronic lymphocytic leukemia patients (2014) (2)
- The role of IL-10 in B-cell chronic lymphocytic leukemia cell survival (2016) (2)
- Comprehensive single nucleotide polymorphism study supports the role of MDM2 in p53-competent chronic lymphocytic leukemia. (2008) (2)
- Characterization of LP-118, a Novel Small Molecule Inhibitor of Bcl-2 and Bcl-Xl in Chronic Lymphocytic Leukemia Resistant to Venetoclax (2021) (2)
- P1269: VIP152 IS A NOVEL CDK9 INHIBITOR WITH IMPROVED SELECTIVITY, TARGET MODULATION, AND CARDIAC SAFETY IN PATIENTS WITH LYMPHOMA (2022) (2)
- Splenic microenvironment is important in the survival and growth of Chronic Lymphocytic Leukemia in mice (2017) (2)
- Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia (2021) (2)
- Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals (2011) (2)
- B-1239, a Novel Anti-BAFF-R Afucosylated Human Antibody, Promotes Potent Natural Killer Cell- Mediated Antibody Dependent Cellular Cytotoxicity In Chronic Lymphocytic Leukemia Cells In- Vitro and Depletion Of Circulating Leukemic CLL B Cells In-Vivo (2013) (2)
- A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL) (2021) (2)
- The Pentostatin, Cyclophosphamide, and Rituximab Regimen (PCR) Is Highly Active and Well Tolerated Regardless of Patient Age, Creatinine Clearance, and Performance Status: Analysis of a Multi-Center Phase II Trial. (2006) (2)
- Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq (2021) (2)
- A phase Ib/II open-label study to evaluate the safety and efficacy of TRU-016 in combination with bendamustine versus bendamustine alone in patients with relapsed chronic lymphocytic leukemia. (2011) (2)
- Targeting PRMT5 to Circumvent Acquired Ibrutinib Resistance in Mantle Cell Lymphoma (2019) (2)
- Utilizing Clinical Features of Progression to Predict Richter's Syndrome in Patients with CLL Progressing after Ibrutinib (2021) (2)
- Loss of Id4 Accelerates CLL Progression in TCL1 Mice (2008) (2)
- Leukemic cell expressed CTLA-4 suppresses T cells via down-modulation of CD80 by trans-endocytosis (2016) (2)
- FcγRIIIa role in rituximab efficacy (2007) (2)
- VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia (2022) (2)
- Germinal Center Generation and Maintenance By T Follicular Helper Cells Is Required For The Development Of Chronic Gvhd Associated Bronchiolitis Obliterans In a Preclinical Model (2013) (2)
- Autophagy Is a Relevant Cellular Process In CLL and Contributes to Drug Resistance of Flavopiridol (2010) (2)
- Contribution of Obinutuzumab to Acalabrutinib Therapy in Patients with Treatment-Naive Chronic Lymphocytic Leukemia: Analysis of Survival Outcomes By Genomic Features (2022) (2)
- Efficacy of a novel schedule of decitabine in previously untreated AML, age 60 or older. (2009) (2)
- Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia (2021) (2)
- Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity In Relapsed and Refractory Non-Hodgkin's Lymphoma. (2010) (2)
- Illness Perceptions in Chronic Lymphocytic Leukemia: Testing Leventhal's Self-regulatory Model. (2018) (2)
- Epigenetic Targeting Via Transcriptional Inhibition of DNA Methyltransferase: a Phase I Study of Bortezomib in Combination with 5-Azacytidine in Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML). (2009) (2)
- A phase 1 study evaluating the safety and tolerability of otlertuzumab , an anti-CD 37 mono-speci fi c ADAPTIR therapeutic protein in chronic lymphocytic leukemia (2014) (2)
- Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia. (2019) (2)
- Performance of Standard Prognostic Models in Older Adults Receiving Ibrutinib for Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL): A Post Hoc Analysis of Alliance A041202 Phase 3 Trial (2021) (2)
- CD37 Expression in Acute Myeloid Leukemia Provides New Target for Directed Therapy (2018) (2)
- The Novel Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Potent Cytotoxicity in Primary Chronic Lymphocytic Leukemia Cells and a Defective NF-κB Response, (2011) (2)
- A Phase I Evaluation of Low Dose Decitabine Targeting DNA Hypermethylation in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin’s Lymphoma (NHL): Dose-Limiting Myelosuppression without Evidence of Hypomethylation (2008) (2)
- Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia. (2019) (2)
- Global Inhibition of Bruton's Tyrosine Kinase (BTK) Delays the Development and Expansion of Chronic Lymphocytic Leukemia (CLL) in the TCL1 Mouse Model of Disease (2012) (2)
- Analysis of Prognostic Factors Predictive of Complete Response (CR) to Ibrutinib in Patients with CLL/SLL (2015) (2)
- A phase 1b trial of duvelisib, a PI3K-δ,γ inhibitor, in combination with obinutuzumab in patients with CLL/SLL previously treated with a Bruton’s tyrosine kinase inhibitor (BTKi). (2015) (2)
- Pharmacologic Inhibition with Duvelisib (IPI-145) and Genetic Inhibition of PI3K p110δ Antagonizes Intrinsic and Extrinsic Survival Signals in Chronic Lymphocytic Leukemia (CLL) (2014) (2)
- Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors (2022) (2)
- In-Hospital Mortality and Trends Associated with Splenectomy in Patients with Immune-Mediated Thrombocytopenia (ITP). (2009) (2)
- Next-Generation Bruton Tyrosine Kinase Inhibitors. (2020) (2)
- Clinical, Laboratory, and Treatment Outcome Characteristics of Chronic Lymphocytic Leukemia (CLL) Patients with p53 Mutations or del(17p) Enrolled on a Prospective Phase III Clinical Trial: Short Progression Free Survival, Irrespective of Fludarabine-Based Treatment Used. (2004) (2)
- Characteristics of Familial CLL Evaluated in the CLL Research Consortium Cohort (2008) (2)
- Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid Leukemia. (2009) (2)
- A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia (2019) (2)
- Successful Management (Mgt) of Hyperkalemia Associated with Tumor Lysis Syndrome (TLS) in Refractory Chronic Lymphocytic Leukemia (CLL) Patients (pts) Receiving Flavopiridol on an Active Pharmacologically Derived Schedule. (2005) (2)
- Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study (2019) (2)
- A Phase 2 Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Llmphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with High-Risk Genomic Features (2016) (2)
- Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients (2013) (2)
- UGT2B17 as a disease accelerator in CLL. (2013) (2)
- Mir-155 Expression Is Associated with Chemoimmunotherapy Outcome and Is Modulated By Bruton’s Tyrosine Kinase Inhibition with Ibrutinib (2014) (2)
- Incidence of Extramedullary Relapse of Acute Myeloid Leukemia Following Transplantation with Busulfan-Based Conditioning Regimens. (2004) (2)
- Phase 1 Study of TRU-016, An Anti-CD37 SMIP™ Protein in Relapsed and/or Refractory NHL Patients (2011) (2)
- A Validated Risk Model for Overall Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia Applicable to Patients Treated with Novel Therapies and Standard of Care (2017) (2)
- FTY720 Demonstrates Promising in-Vitro and in-Vivo Pre-Clinical Activity by Down-Modulation of Cyclin D1 and Pakt in Mantle Cell Lymphoma. (2009) (2)
- Updated Results from a Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL) and Richter's Transformation or Ibrutinib for Patients with Ibrutinib-Resistant Clones (2016) (2)
- Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Who Have Undergone Prior Allogeneic Stem Cell Transplant (2015) (2)
- Phase 1 Trial of Decitabine and Bortezomib in High Risk Acute Myeloid Leukemia (AML) (2010) (2)
- Unacceptable Toxicity of Lenalidomide When Administered to CLL Patients at Higher Doses. (2007) (2)
- Developing a Novel Class of Drug to Inhibit Protein Arginine Methyltransferase 5 (PRMT5) Enzyme Dysregulation in Mantle Cell Lymphoma (2011) (2)
- Venetoclax for Chronic Lymphocytic Leukaemia Progressing after Ibrutinib: a Multicentre, Open-Label Phase 2 Trial (2018) (2)
- A 17-Gene Leukemia Stem Cell (LSC) Score in Adult Patients (Pts) with Acute Myeloid Leukemia (AML) Reveals a Distinct Mutational Landscape and Refines Current European Leukemianet (ELN) Genetic Risk Stratification (2018) (2)
- CD19 Targeting of Lymphoid Malignancies by Novel Fc-Domain Engineered Monoclonal Antibody. (2009) (2)
- A New Role for Lyn in the CLL Microenvironment. (2016) (2)
- Molecular biology of chronic leukemias (2015) (1)
- Lumiliximab (anti-CD23 antibody) mediates apoptosis and antitumor activity in chronic lymphocytic leukemia (CLL) cells and CD23+ lymphoma cell lines (2007) (1)
- Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at Enrolling Institutions Compared to Central Laboratory Results in the Beat AML Master Trial (2019) (1)
- VIP152 Is a Novel CDK9 Inhibitor with Efficacy in Chronic Lymphocytic Leukemia (2021) (1)
- Poster session 6. Phase 1 studies (2013) (1)
- IL-21 Promotes Apoptosis through Induction of the BH3 Only Protein Bim and Enhacnes Direct and Innate Immune-Promoted Death of Chronic Lymphocytic Leukemia Cells. (2007) (1)
- Abstract 1938: Store-operated calcium signaling is an effective therapeutic target in AML (2018) (1)
- Factors That Influence Patient Treatment Decision Making in the Era of Novel Agents: An Internet-Based Survey of 281 Patients with CLL (2016) (1)
- 3.23 Targeted Nanoparticle Delivery Overcomes Off-Target Immunostimulatory Effects of Oligonucleotides and Improves Therapeutic Efficacy (2011) (1)
- Sequential Phase II Studies of Flavopiridol by 72-Hour Continuous Infusion and 1-Hour Intravenous Bolus for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia: Results from CALGB Study 19805. (2004) (1)
- Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib (2022) (1)
- Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib. (2019) (1)
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Entospletinib in Combination with Intensive Induction and Consolidation Chemotherapy in Adults with Newly Diagnosed N ucleophosmin 1-mutated Acute Myeloid Leukemia (2021) (1)
- The 2017 European Leukemianet Genetic Risk Classification Performs Poorly in Older Patients with Acute Myeloid Leukemia (AML) and Should be Refined to Identify Patients Requiring Additional or Alternative Treatment (2019) (1)
- PS1122 RECURRENT XPO1 MUTATIONS IDENTIFIED AS PREDICTIVE MARKER FOR ADVANCED CLL PROGRESSION (2019) (1)
- Methylation of the Tumor Suppressor Gene PTPRO (Receptor-Type Protein Tyrosine Phosphatase) Is Associated with Expression of Important Apoptosis-Related Proteins in Chronic Lymphocytic Leukemia (CLL). (2004) (1)
- Chronic Lymphocytic Leukemia and Related Chronic Leukemias (2006) (1)
- Diagnostic utility of bronchoscopy in newly diagnosed acute leukemia patients. (2020) (1)
- The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia (2019) (1)
- Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials. (2011) (1)
- Progressive Epigenetic Programming during B Cell Maturation Is Reflected in a Continuum of Epigenetic Disease Phenotypes in Chronic Lymphocytic Leukemia (2015) (1)
- Sweet-Like Eruption Associated With Obinutuzumab Therapy for Chronic Lymphocytic Leukemia. (2017) (1)
- Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia (2022) (1)
- Presence of a Translocation Is Associated with Short Time to Treatment from Diagnosis in IGHV Mutated Chronic Lymphocytic Leukemia (CLL) Patients (2016) (1)
- NPM1 mutations Using Deep Amplicon Sequencing and Broad Next Generation Sequencing at the Time of Complete Remission Is Informative to Predicting Risk of Relapse Following Intensive Chemotherapy (2019) (1)
- Vitro Activity Against Human B-Cell Chronic Lymphocytic Leukemia Cells Depsipeptide ( FR 901228 ) : A Novel Therapeutic Agent With Selective , In (1999) (1)
- Pharmacokinetics and Tolerability of the Novel Non-immunosuppressive Fingolimod Derivative, OSU-2S, in Dogs and Comparisons with Data in Mice and Rats (2020) (1)
- Hunting for the Achilles' heel of CLL. (2009) (1)
- Priming of Mir-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine. (2012) (1)
- Controlled variable selection in Weibull mixture cure models for high‐dimensional data (2022) (1)
- Histone Deacetylase Inhibitors Induce microRNAs Targeting BTK in Acute Myeloid Leukemia (2015) (1)
- Updated results of a phase I study of low dose decitabine and valproic acid (VA) in patients with acute myeloid leukemia (AML): Gene reexpression, demethylation, and clinical response. (2006) (1)
- Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center (2016) (1)
- Preclinical Characterization of TP‐0903, a Novel Multikinase Inhibitor, in TP53 Mutant Acute Myeloid Leukemia (2021) (1)
- Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (2019) (1)
- Attainment of Minimal Residual Disease Negative State Is Crucial for Successful Outcome of Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Advanced Chronic Lymphocytic Leukemia (CLL). (2008) (1)
- A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab: Evidence of Clinical Activity in the Absence of del(17p13.1) Genomic Abnormalities. (2004) (1)
- Abstract 2591: Ibrutinib can reverse established chronic graft-versus-host disease, which is dependent upon IL-2 inducible T-cell kinase (ITK) and Bruton's tyrosine kinase (BTK)-driven lymphocyte activation (2014) (1)
- Silvestrol, a Rocaglate Derivative from the Indonesian Plant Aglaia foveolata , Has Significant Bcl-2- and p53-Independent Anti-Tumor Activity against Chronic Lymphocytic Leukemia Cells. (2006) (1)
- Arsenic Trioxide and Ascorbic Acid Enhances the Cytotoxicity of Hu1D10 towards CLL Cells. (2004) (1)
- The Role of Tetraspanin CD37 in B-Cell Malignancy (2015) (1)
- Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential (2022) (1)
- A Precision Medicine Heirarchical Classification Developed Using Variant Allele Frequency (VAF) for Treatment of Older Patients (Pts) with Acute Myeloid Leukemia (AML): Alliance Clinical Trials in Oncology (Alliance) Historical Patient Control (2018) (1)
- Chronic lymphocytic leukemia: state of the art and beyond. (2014) (1)
- Tumor Antigen ROR1 Targeted Delivery Of FTY720 Derivative OSU-2S Prolongs Survival In ROR1 Engineered Mouse Model Of Chronic Lymphocytic Leukemia (2013) (1)
- Increasing Genetic Complexity Predicts for Inferior Outcomes Following Reduced-Intensity Conditioning Allogeneic Transplant for Chronic Lymphocytic Leukemia (2011) (1)
- Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy (2019) (1)
- Role and regulation of microRNAs targeting BTK in acute myelogenous leukemia (2018) (1)
- Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL) (2020) (1)
- Heterogeneity and Evolution Of DNA Methylation In Chronic Lymphocytic Leukemia (2013) (1)
- Toxicities and Related Outcomes of Elderly Patients (pts) (≥65 Years) with Hematologic Malignancies in the Contemporary Era (Alliance A151611) (2016) (1)
- Abstract 819: High response rates with entospletinib in patients with t(v;11q23.3);KMT2Arearranged acute myeloid leukemia and acute lymphoblastic leukemia (2018) (1)
- Serum chemokines and cytokines in CLL patients treated with duvelisib, a PI3K-δ,γ inhibitor. (2015) (1)
- Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib (2020) (1)
- Evaluation of the Incidence and Risk Factors Associated with Bleeding Events in Patients Receiving Acalabrutinib Therapy (2021) (1)
- Factors That Influence Treatment Decision-Making: Perspectives of 1147 Chronic Lymphocytic Leukemia (CLL) Patients in the United States (2018) (1)
- Abstract 2014: Modulation of DNA methyltransferases in leukemia cells by curcumin and its associated anti-leukemia activities (2011) (1)
- MicroRNA (miRNA)-29b Targets DNMT3A and B and Induces Re-Expression of the Hypermethylated ESR1 and p15 Genes in Acute Myeloid Leukemia (AML). (2007) (1)
- HDAC1 regulates the chromatin landscape to establish transcriptional dependencies in chronic lymphocytic leukemia (2020) (1)
- An Innovative Telemedicine Platform to Provide Expert Access to Patients with Chronic Lymphocytic Leukemia (CLL) (2019) (1)
- Natural History of Non-Infectious, Ibrutinib-Attributable Adverse Events Leading to Alternative BTK Inhibitor Use in CLL (2016) (1)
- Incidence of and Risk Factors for Major Hemorrhage in Patients Treated with Ibrutinib: Results from an Integrated Analysis (2017) (1)
- Differential regulation of CTLA4 expression through BTK-dependent and independent mechanisms in CLL (2022) (1)
- Distress and Perceived Impact on Well-Being for Low- or Intermediate-Risk and High-Risk Patients with Chronic Lymphocytic Leukemia (CLL) (2016) (1)
- Incidence, Type, and Management of Venous and Arterial Thrombosis during Ibrutinib Treatment (2018) (1)
- Magnetic Tweezers-based 3D Microchannel Electroporation for Efficient Cell Manipulation and High-Throughput Gene Transfection (2015) (1)
- Red blood cells differentiated in vitro using sequential liquid and semi-solid culture as a pre-clinical model (2021) (1)
- Co-Treatment with Milatuzumab (Anti-CD74 mAb) and Rituximab (Anti-CD20 mAb) Results in the Induction of Mantle Cell Lymphoma Cell Death That Is Dependent On Actin Polymerization and Inhibition of NF-Kb. (2009) (1)
- Critical Molecular Studies to Strategically Plan Therapy in Chronic Lymphocytic Leukemia (CLL): Correlating Cellular Proteins with Defined Prognostic Patient Subsets and Their Response to Treatment. (2004) (1)
- Motexafin Gadolinium Induces Apoptosis in Lymphoid Cell Lines and Demonstrates Enhanced Biological Activity with Akt Kinase Inhibitors. (2004) (1)
- Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia. (2021) (1)
- Role of CD37SMIP a Novel Engineered Small Modular Immunopharmaceutical in the Treatment of CLL. (2007) (1)
- Lenalidomide-Dependent Activation of the Phosphatidylinositol 3-kinase-δ Pathway Is Antagonized by CAL-101 In Chronic Lymphocytic Leukemia (2010) (1)
- Abstract 1541: Evaluation of ROR1 targeted antibody drug conjugate in ROR1 positive leukemia (2019) (1)
- OSU-2S, A Novel FTY720 derivative, Mediates Cytotoxicity In Chronic Lymphocytic Leukemia Through PKC Dependent Modulation of SHP1 Tyrosine Phosphatase (2011) (1)
- A Next-Generation Sequencing-Based Karyotyping Algorithm Reveals the Genomic Structure of Acute Myeloid Leukemia (2018) (1)
- A phase II study of MOR208 plus idelalisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyrosine kinase inhibitor (MIRACLE). (2016) (1)
- Genomic Analysis of Cellular Hierarchy in Acute Myeloid Leukemia Using Ultrasensitive LC-FACS-Seq (2019) (1)
- Identification of the Histone Deacetylase Inhibitor (HDACi), AR-42, as a Novel Anti-Leukemia Stem Cell Agent in Acute Myeloid Leukemia (AML). (2009) (1)
- Haematologic and immunologic function and patient-reported outcomes for the phase 3 RESONATE (TM) study of ibrutinib versus ofatumumab in relapsed/refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma (2015) (1)
- BRAFV600E Accelerates Disease Progression and Increases Immune Suppression in a Mouse Model of B-Cell Leukemia (2016) (1)
- Therapeutic Targeting of the RAS-Pathway by Synthetic Mir-181a Nanoparticles in Acute Myeloid Leukemia (AML). (2012) (1)
- Preliminary results of a phase I trial with dose escalated lenalidomide (L) in separate cohorts of relapsed acute leukemia (AL) or chronic lymphocytic leukemia (CLL): evidence of activity in acute myeloid leukemia (AML) and toxicity in CLL at starting dose (2008) (1)
- A new twist for CD38 antigen expression in CLL (2005) (1)
- High Early Death Rates, Treatment Resistance and Short Survival of Black Adolescent and Young Adults (AYAs) with Acute Myeloid Leukemia (AML) (Alliance) (2021) (1)
- Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia (2022) (1)
- RANDOMIZED COMPARISON OF IBRUTINIB VERSUS OFATUMUMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA: RESULTS FROM THE PHASE III PCYC-1112 RESONATE((TM)) TRIAL (2014) (1)
- Type of prior genotoxic insult determines the genomic characteristics of therapy‐related myeloid neoplasms (2021) (1)
- Perceived risk for cancer progression and psychological status in chronic lymphocytic leukemia patients: CALGB 70603 (Alliance) (2019) (1)
- Durable Responses Including Complete Responses in CLL Following Long Term Treatment With Single-agent Ibrutinib 420 mg (2015) (1)
- OSU-2S, a Novel PKC Activator, Mediates PKC Dependent Cell Death, Differentiation and Cell Cycle Arrest in Acute Myeloid Leukemia (2017) (1)
- Immunophenotypic characterization of relapsed chronic lymphocytic leukemia patients treated with lumiliximab in combination with FCR (2008) (1)
- Phase I Trial of Flavopiridol In Relapsed Myeloma: Brief Response In t(4;14) with Significant Neutropenia (2010) (1)
- Flavopiridol Treatment of Patients Aged 70 or Older with Refractory or Relapsed Chronic Lymphocytic Leukemia Is Feasible and Not Associated with Adverse Outcome When Compared to Younger Patients (2010) (1)
- OSU-T315, An Integrin-Linked Kinase (ILK) Inhibitor, Induces Apoptosis By Targeting B Cell Receptor and CD49d Mediated AKT/ERK Activation In Chronic Lymphocytic Leukemia Cells (2013) (1)
- Exploring the Role of the Recurrent Exportin 1 (XPO1/CRM1) Mutations E571G and E571K in Chronic Lymphocytic Leukemia (2016) (1)
- Excessive Neurotoxicity in a Phase II Trial of Combined Bortezomib and Rituximab in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin’s Lymphoma. (2006) (1)
- Evaluation of ROR1 Targeted Antibody Drug Conjugates in Acute and Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma (2017) (1)
- SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model (2016) (1)
- Barriers to Proceeding to Reduced-Intensity Allogeneic Stem Cell Transplant in Chronic Lymphocytic Leukemia (2013) (1)
- Hypertension Development, Management, and Cardiovascular Events Following Ibrutinib Initiation for Hematologic Malignancies (2018) (1)
- del(17p13.1) in Chronic Lymphocytic Leukemia Confers Poor Prognosis Even at Low Percentage Involvement and Increases Proportionately with Increase in Clonal Involvement. (2007) (1)
- Select high risk genetic features predict earlier progression following chemotherapy in chronic lymphocytic leukemia: Prospective randomized trial (Intergroup E2997) to evaluate justification for risk-adapted therapy. (2006) (1)
- High-Level Expression of ROR1 Associates with Early Disease Progression in Patients with Chronic Lymphocytic Leukemia (2015) (1)
- FCGR3A and FCGR2A Polymorphisms May Not Correlate with Response to Alemtuzumab (Campath-1H) in Chronic Lymphocytic Leukemia (CLL) (2013) (1)
- Cellular Uptake and Intracellular Levels of the Bcl-2 Antisense G 3139 in Cultured Cells and Treated Patientswith AcuteMyeloid Leukemia (2005) (1)
- Phase I Study Of Vorinostat (SAHA) After Autologous Transplant For Patients With High Risk Lymphoma (2010) (1)
- Additional Gene Mutations Refine the 2017 European Leukemianet (ELN) Classification of Adult Patients (Pts) with De Novo Acute Myeloid Leukemia (AML) Aged <60 Years: An Analysis of Alliance for Clinical Trials in Oncology (Alliance) Studies (2018) (1)
- Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study (2023) (1)
- Illness representations and psychological outcomes in chronic lymphocytic leukaemia. (2021) (1)
- Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutations (2020) (1)
- Acalabrutinib With Obinutuzumab in Treatment‐Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: 3‐Year Follow‐Up (2019) (1)
- P682: NEMTABRUTINIB (MK-1026), A NON-COVALENT INHIBITOR OF WILD-TYPE AND C481S MUTATED BRUTON TYROSINE KINASE FOR B-CELL MALIGNANCIES: EFFICACY AND SAFETY OF THE PHASE 2 DOSE-EXPANSION BELLWAVE-001 STUDY (2022) (1)
- Cardiovascular Magnetic Resonance Imaging in Patients With Ibrutinib-Associated Cardiotoxicity. (2023) (1)
- Exploring the Functional Relevance of BTK Beyond Chronic Lymphocytic Leukemia (CLL) Cells: BTK Expression in Non-Malignant Immune Cells of the Microenvironment Mediates CLL Development and Progression In Vivo (2016) (1)
- Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib (2022) (1)
- A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome (2020) (1)
- FTY720, a New and Alternative Strategy for Treating Blast Crisis CML and Ph 1 ALL Patients. (2006) (1)
- Abstract 119: AR42, a histone deacetylase inhibitor (HDACI), increases microRNA (miR)-29b and sensitizes cells to decitabine (DAC) treatment: A novel epigenetic-targeting approach in acute myeloid leukemia (AML) (2012) (1)
- Decitabine-Induced Differentiation Syndrome in a Patient with Acute Myeloid Leukemia: A Case Report. (2004) (1)
- in chronic lymphocytic leukemia Selective inhibitors of nuclear export show that CRM1/XPO1 is a target (2013) (1)
- The Novel Histone Deacetylase Inhibitor OSU-HDAC42 Has Class I and II Histone Deacetylase (HDAC) Inhibitory Activity and Represents a Novel Therapy for Chronic Lymphocytic Leukemia. (2006) (1)
- LYMPHOID NEOPLASIA Targeting BTK through microRNA in chronic lymphocytic leukemia (2016) (0)
- Neurofibromin 1 gene Mutations Are Recurrent Events in Adult Patients with Acute Myeloid Leukemia (AML), Associate with Poor Outcome and Refine the Adverse European Leukemianet (ELN) Risk Category (2017) (0)
- Molecular Landscape in Acute Myeloid Leukemia (AML) Patients (pts) from Mexico As an Initial Study to Identify Healthcare Disparities in Hispanic Populations: Alliance for Clinical Trials in Oncology [Alliance] (2022) (0)
- Abstract 2966: Exploring the therapeutic potential of a novel Siglec-6 targeted bispecific antibody to selectively kill leukemia cells (2023) (0)
- Epigenetic Phenocopying Expands Molecular Risk Assessment in Acute Myeloid Leukemia (Alliance) (2021) (0)
- Fatigue, Distress, and Quality of Life As Covariates for Early-Stage Chronic Lymphocytic Leukemia (2012) (0)
- Comparative Assessment of Different Clinically Utilized CD20 Directed Antibodies in Chronic Lymphocytic Leukemia (CLL) Cells Reveals Divergent NK-Cell, Monocyte and Macrophage Properties, (2011) (0)
- Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up (2022) (0)
- Inconsistent associations between recombination rate and codon bias across Drosophila species (0)
- Distinct biomarkers as prognostic in chronic lymphocytic leukemia patients treated with alvocidib and lenalidomide as single agents or combination regimens thereof. (2014) (0)
- Abstract 3014: BCL3 over-expression contributes anin vivogrowth advantage in a B-cell lymphoma xenograft model and is a risk factor for ibrutinib relapse in CLL (2017) (0)
- Abstract 4406: ROR1 targeted delivery of OSU-2S, a non-immunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle cell lymphomain-vitroandin-vivo (2015) (0)
- Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL (2019) (0)
- Regularized Mixture Cure Models Identify a Gene Signature That Improves Risk Stratification within the Favorable-Risk Group in 2017 European Leukemianet (ELN) Classification of Acute Myeloid Leukemia (Alliance 152010) (2022) (0)
- Uniparental Disomies (UPD) of Chromosome 13q Is Associated with Shorter Disease-Free Survival in Adult Patients (Pts) with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (2018) (0)
- Methylation and Silencingof Protein Tyrosine Phosphatase Receptor Type O in Chronic Lymphocytic Leukemia (2007) (0)
- Key points (2019) (0)
- Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial (2021) (0)
- Abstract 2578: Synergistic activity of lenalidomide and interleukin-21 in chronic lymphocytic leukemia (2014) (0)
- Abstract 553: Ibrutinib, a BTK inhibitor, impairs the generation and function of myeloid derived suppressor cells (2016) (0)
- CN4 Patient-Reported Outcomes from the Phase 3, Randomized Study of Acalabrutinib with or without Obinutuzumab Versus Chlorambucil PLUS Obinutuzumab for Treatment-Naïve Chronic Lymphocytic Leukemia (ELEVATE-TN) (2021) (0)
- HDAC Inhibitors and Cardiac Safety (2007) (0)
- Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine. (2009) (0)
- Leflunomide Inhibits Proliferation of Neoplastic B-Cell Lines and Induces Apoptosis in Primary CLL Cells. (2004) (0)
- Non-Hodgkin's LymphomasPractice Guidelines in Oncology TM (2010) (0)
- cyclophosphamide, and rituximab lymphocytic leukemia patients treated with pentostatin, Mcl-1 expression predicts progression-free survival in chronic (2013) (0)
- Precision Medicine Advances Positive Outcomes in AML (2021) (0)
- Single Institution Experience with Two High-Dose Chemotherapy (HDC) Conditioning Regimens Prior to Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM). (2004) (0)
- Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial. (2023) (0)
- Novel role of B cell receptor signaling in regulation of Tcl1, an oncogene, and Par-4, a tumor suppressor gene, in B cell chronic lymphocytic leukemia (IRM10P.619) (2015) (0)
- Evaluation of the Incidence and Risk Factors Associated with Major Cardiovascular Events in Patients Receiving Acalabrutinib Therapy (2020) (0)
- Delineating the mechanistic pathway and therapeutic potential of Siglec-6 in Chronic Lymphocytic Leukemia (2022) (0)
- Glycovariant CD37 Small Modular Immuno-Pharmaceutical (TruADhanCe™ SMIP) Promotes Enhanced Natural Killer Cell Mediated Cytotoxicity against Primary Chronic Lymphocytic Leukemia Cells. (2009) (0)
- 102 – Chronic Lymphocytic Leukemia (2014) (0)
- Interpretation of IGHV and Interphase Cytogenetics at Diagnosis of a Patient With Chronic Lymphocytic Leukemia (2016) (0)
- Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with CLL: phase 3 analysis (2019) (0)
- Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma , Version 2 . 2019 CE (2019) (0)
- Effect of auranofin on oxidative and endoplasmic reticulum stress as well as anti-CLL activity with proteasome inhibitor. (2012) (0)
- New Therapies in Chronic Lymphocytic Leukemia (2008) (0)
- CCTG on the world stage at ASCO 2017 (2020) (0)
- TLR7/8 agonists enhance FcγR in CLL patient monocytes (TUM7P.958) (2014) (0)
- Abstract B44: Pharmacologic inhibition with IPI-145 and genetic inhibition of PI3K p110δ antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia (2015) (0)
- The NCCN Non-Hodgkin ’ s Lymphomas Clinical Practice Guidelines in OncologyTM (2010) (0)
- Outcome Prediction By the New 2022 European Leukemia Net (ELN) Genetic-Risk Classification for Adult Patients (Pts) with Acute Myeloid Leukemia (AML): An Alliance Study (2022) (0)
- Using HSP90 Inhibitors to Target DNA Repair Proteins in AML (2018) (0)
- Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL) (2022) (0)
- Abstract 1517: The integration of bulk DNA sequencing and single-cell analysis reveals diverse clonal evolution in CLL patients treated with BTKi (2020) (0)
- Recurrent Genetic Variants of Long Non-Coding RNAs (lncRNAs) Independently Associate with Clinical Outcome of Younger Adults with Cytogenetically Normal Acute Myeloid Leukemia (2017) (0)
- nejmoa1509981 appendix (1) (2016) (0)
- Divergent NK Cell , Monocyte , and Chronic Lymphocytic Leukemia Cells Utilized CD 20-Directed Antibodies in Comparative Assessment of Clinically (2013) (0)
- Abstract 1060: Introducing a novel DHODH inhibitor with superior in vivo activity as monotherapy or in novel combination regimen with immunotherapy for hematological malignancies (2022) (0)
- Abstract CT244: A Phase 1/2 study evaluating the safety and efficacy of IOV-2001 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (2021) (0)
- patients with de novo acute myeloid leukemia : results from Cancer and success , cumulative incidence of relapse , and overall survival in adult Pretreatment cytogenetic abnormalities are predictive of induction (2002) (0)
- leukemogenic selection high-risk disease and reflects antigen-driven, post-germinal-center Use of IGHV3-21 in chronic lymphocytic leukemia is associated with (2013) (0)
- Updated Results of a Phase I Study of Flavopiridol in Acute Leukemias Using a Novel, Pharmacokinetically Derived Schedule: Clinical Activity Including Hyperacute Tumor Lysis Syndrome (TLS), Pharmacokinetics (PK), and Pharmacodynamics (PD). (2006) (0)
- independent mechanism - Bcl-2 CLL cells and transformed B-cell lymphoma cell line via a caspase- and A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary (2013) (0)
- TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion (2022) (0)
- Abstract 1620: Clonal hematopoiesis of indeterminate potential in the companion dog (2022) (0)
- 50. Different cytogenetic culture conditions yield surprising results (2018) (0)
- Identification of PTPN11 mutations As Early Events in the Development of Acute Myeloid Leukemia (2022) (0)
- Non-Hodgkin’s Lymphomas (1999) (0)
- HDAC1 regulates the chromatin landscape to control transcriptional dependencies in chronic lymphocytic leukemia. (2022) (0)
- Evaluation of membrane bound IL-21 expanded natural killer cells for chronic lymphocytic leukemia therapy (2021) (0)
- Characterization of Survival Outcomes and Clinical and Molecular Modulators in Adult Patients with Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) Treated with Hidac Consolidation: An Alliance Legacy Study (2022) (0)
- A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML) (2022) (0)
- Identification of Novel Synthetic Lethal Partners of NAMPT Inhibitor By CRISPR-Cas9 Screens in Acute Myeloid Leukemia (2019) (0)
- In Vitro and In Vivo Evidence That TSC-22 Is a Putative Tumor Suppressor Gene in Primary Murine and Human Leukemia. (2006) (0)
- A Novel Inhibitor of FLT3 and Its Drug-Resistant Mutants with Superior Activity to Gilteritinib in Molm-13 Preclinical Acute Myeloid Leukemia Xenograft Model (2022) (0)
- Outcomes of patients with multiple myeloma treated with novel agents followed by autologous stem cell transplantation: A retrospective study (2010) (0)
- Leflunomide derivative A77 1726 has antiproliferative and cytotoxic effects upon neoplastic B-cell lines, and is cytotoxic to human chronic lymphocytic leukemia cells (2005) (0)
- Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial (2021) (0)
- P667: LONG-TERM EFFICACY OF ACALABRUTINIB-BASED REGIMENS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND HIGHER-RISK GENOMIC FEATURES: POOLED ANALYSIS OF CLINICAL TRIAL DATA (2022) (0)
- Expression of T Cell Co-Stimulator (ICOS) and Its Ligand and Disease Progression in B-Cell Chronic Lymphocytic Leukemia. (2005) (0)
- Toll-like receptor 2 ligands enhance monocyte Fcγ receptor function (68.16) (2012) (0)
- Brief report The role of phosphatidylinositol 3-kinase- (cid:1) in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia (2011) (0)
- Upgrade to the EPICS Control System at the Argonne Wakefield Accelerator Test Facility (2021) (0)
- Ramasamy myeloid leukemia in acute microRNA-181 a upregulates expression of the antileukemic-p 30 protein α Lenalidomide-mediated enhanced translation of C / EBP (2012) (0)
- Cytogenetic Studies of 539 Chronic Lymphocytic Leukemia (CLL) Patients. (2005) (0)
- Correction: Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq (2021) (0)
- Mutations in Genes Associated with Familial Predisposition to Myeloid Neoplasms: Their Frequency and Associations with Pretreatment Characteristics in Adult Patients (Pts) with Presumably Sporadic De Novo Acute Myeloid Leukemia (AML) (2018) (0)
- The Addition of CT Scans to NCI-96 Chronic Lymphocytic Leukemia (CLL) Response Criteria Fails To Improve the Predictive Power of Complete Response (CR) and Partial Response (PR) as Assessed by Improvement in Progression-Free (PFS) and Overall Survival (OS) . (2006) (0)
- Race-Ethnic Enrollment Disparities over 15 Years of Alliance/CALGB Acute Myeloid Leukemia Clinical Trials, Biobanks, and Correlative Science Protocols (2021) (0)
- Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy (2022) (0)
- APhase 2 Study of Rituximab in Combinationwith Recombinant Interleukin-2 for Rituximab-Refractory Indolent Non-Hodgkin ’ s Lymphoma (2006) (0)
- Ibrutinib for del(17p13.1) CLL Patients: A Potential Bonanza (2013) (0)
- Dependence on Functional p53 Activation of Caspase-3 Without Evidence of bcl-2 Modulation or Flavopiridol Induces Apoptosis in Chronic Lymphocytic Leukemia Cells Via (2011) (0)
- Therapeutics , Targets , and Chemical Biology Aurano fi n Induces Lethal Oxidative and Endoplasmic Reticulum Stress and Exerts Potent Preclinical Activity against Chronic Lymphocytic Leukemia (2014) (0)
- Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention (2022) (0)
- Genomics of primary chemoresistance and remission induction failure in pediatric and adult acute myeloid leukemia (2016) (0)
- Recent Genetic Studies of Adult Patients with Acute Myeloid Leukemia Performed by the Cancer and Leukemia Group B (2001) (0)
- PF232 PROGNOSTIC IMPACT OF THE 2017 EUROPEAN LEUKEMIANET (ELN) CLASSIFICATION OF YOUNGER ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED ON CANCER AND LEUKEMIA GROUP B (CALGB)/ALLIANCE PROTOCOLS (2019) (0)
- The Histone Deacetylase Inhibitor Depsipeptide Mediates Distinct Patterns of Histone Acetylation in Cells Overexpressing Bcl-2. (2004) (0)
- DNA Methylation-Based Classification Highlights the Role of the JAK-STAT Pathway in Acute Myeloid Leukemia (2019) (0)
- Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy (2018) (0)
- Streamlined Operational Approaches and Use of e-Technologies in Clinical Trials: Beat Acute Myeloid Leukemia Master Trial (2021) (0)
- Type of prior genotoxic insult determines the genomic characteristics of therapy-related acute myeloid leukemia. (2020) (0)
- The Multi-CDK Inhibitor Dinaciclib Shows Synergistic Activity with the BET Inhibitor PLX51107 and Reverses BET Resistance through Inhibition of Canonical Wnt Signaling in Acute Myeloid Leukemia (AML) (2022) (0)
- Pharmacokinetics and Tissue Disposition of Lenalidomide in Mice (2012) (0)
- CT Scans in Response and Follow-Up Assessment of CLL: Can We Eliminate Their Use? (2011) (0)
- Abstract 2335: DHODH inhibition modulates T cell metabolism reducing GVHD and prevents relapse following allogeneic HCT (2022) (0)
- Tumor Debulking and Reduction in Risk of Tumor Lysis Syndrome with Single-Agent Ibrutinib (2017) (0)
- Protein Arginine Methyltransferase 5 (PRMT5) Over-Expression Is Essential for Epstein-Barr Virus-Driven B-Cell Transformation. (2012) (0)
- Poster: CLL-139: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naïve Chronic Lymphocytic Leukemia: ELEVATE-TN 4-Year Follow-up (2021) (0)
- Abstract 2260: Evaluating a rare t(X;14)(q28;q32) translocation reveals MTCP1 as a driving factor in chronic lymphocytic leukemia (2021) (0)
- Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients (2021) (0)
- Molecular and Clinical Features of FLT3 Juxtamembrane Domain Point Mutations (muts) in Acute Myeloid Leukemia (AML) (2022) (0)
- Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor Accentuates CD47 Blockade Therapy Resulting in Long Term Survival in Acute Myeloid Leukemia (2022) (0)
- Toll-like receptor 2 ligands enhance monocyte Fc{gamma} receptor function (2012) (0)
- response to therapy distinct molecular characteristics and does not indicate a suboptimal Prolonged lymphocytosis during ibrutinib therapy is associated with (2014) (0)
- LP-118, a Selective Bcl-2 Inhibitor with Tuned Bcl-Xl Activity, Causes Myeloid Differentiation and Cell Death in Acute Myeloid Leukemia (AML) (2022) (0)
- Lymphocyte Cytosolic Protein 1 (LCP1) Is a Membrane Associated Molecular Target in Chronic Lymphocytic Leukemia and Is Activated in Microenvironment Signaling (2012) (0)
- NF-κB Is Active in Mcl-1 Promoter Regulation in Human CLL. (2008) (0)
- The HSP90 Inhibitor 17-DMAG Targets NF-κB to Induce Apoptosis in CLL and Prolongs Survival in a CLL Mouse Model. (2009) (0)
- Diagnostic utility of bronchoscopy in newly diagnosed acute leukemia patients (2021) (0)
- Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. (2022) (0)
- To Catch a Killer: Delineating the Mechanistic Role of Siglec-6, a Novel Glycoprotein Target, for the Treatment of Chronic Lymphocytic Leukemia (2022) (0)
- A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and I n Vi tro Potency in B-Cell Malignancies (2015) (0)
- Genomic and Proteomic Analysis of Primary Chemoresistance and Induction Failure in Acute Myeloid Leukemia (2015) (0)
- Recurrent Mutations in EGR2 Direct Specific Epigenetic Reconfiguration in Chronic Lymphocytic Leukemia (2018) (0)
- intracellular calcium leukemia cells with impaired oxygen consumption and mobilization of Flavopiridol causes early mitochondrial damage in chronic lymphocytic (2013) (0)
- Comment on Hewamana et al , page 4681 CLL and activated NF-B : living partnership (2008) (0)
- Prognostic role of beta-2 microglobulin (B2M) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients (pts) treated with ibrutinib (ibr). (2018) (0)
- LYMPHOID NEOPLASIA Assessment of CD37 B-cell antigen and cell of origin signi fi cantly improves risk prediction in diffuse large B-cell lymphoma (2016) (0)
- Differential Impact of Prognostically Significant Gene Mutations in Acute Myeloid Leukemia (AML) Patients (Pts) Older Than 70 Years (y) Treated with Cytarabine-Based Induction Therapy (2020) (0)
- Evaluation of bleeding events in patients receiving acalabrutinib therapy. (2023) (0)
- Role of Prostate apoptosis response-4 tumor suppressor in the survival and growth of Chronic Lymphocytic Leukemia (2015) (0)
- Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results (2012) (0)
- Metaphase Cytogenetics in Chronic Lymphocytic Leukemia (2016) (0)
- IL-21 enhances chemoimmunotherapy mediated death of chronic lymphocytic leukemia cells (2007) (0)
- Is Chemotherapy the Standard for Asymptomatic Androgen- Independent Prostate Cancer? (2008) (0)
- Outcomes with Ibrutinib by Line of Therapy in Patients with CLL: Analyses from Phase 3 Data (2016) (0)
- Activity of the multikinase inhibitor TP‐0903 in RAS mutant acute myeloid leukemia (2020) (0)
- Author Correction: An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia (2023) (0)
- ROR1 directed delivery of FTY720 derivative OSU-2S mediates potent cytotoxic activity against chronic lymphocytic leukemia but not normal B cells in-vitro and in ROR1 expressing transgenic CLL mouse model in-vivo (P3275) (2013) (0)
- Traditional treatment approaches in chronic lymphocytic leukemia. (2014) (0)
- Abstract CT132: Long-term treatment with single-agent ibrutinib 420 mg leads to durable responses including complete responses in CLL (2015) (0)
- Trends in pneumonia (PNA) hospitalization among patients (pts) with chronic lymphocytic leukemia (CLL). (2009) (0)
- OSU-2S: a novel non-immunosuppressive FTY720 derivative mediates potent cytotoxic activity through PKC dependent phosphorylation of tumor suppressor SHP1 and down modulation of Tcl1 oncogene in chronic lymphocytic leukemia (P2120) (2013) (0)
- Raji-Burkitt ’ s LymphomaModel for Preclinical andMechanistic Evaluation of CD 52-Targeted Immunotherapeutic Agents (2008) (0)
- Dose-dependent activity of decitabine in Kasumi-1 cells (2011) (0)
- Survivalof B Cell Development, Differentiation, and Stages Element Binding Protein-1 in Multiple Differential Role for Cyclic AMP Response (2006) (0)
- Resistance to the Novel Translation Inhibitor Silvestrol Is Mediated by Elevated Mcl-1 Expression. (2009) (0)
- Stereotypic IGHV3-21/IGLV3-21 Antibodies Expressed in High-Risk Chronic Lymphocytic Leukemia Bind Peptostreptococcus Magnus Protein L. (2007) (0)
- CLL Whole-Genomic Sequencing Notches Up Our Understanding of the Disease (2011) (0)
- Immunoliposomal Delivery of Mir-29b By Targeting Tumor Antigen ROR1 Induces Epigenetic Reprograming in Human-ROR1-Expressed Mouse Model of Chronic Lymphocytic Leukemia (2015) (0)
- A critical role for Akt in macrophage cytotoxicity to antibody‐coated tumor cells (2007) (0)
- Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis (2019) (0)
- Modulation of CYP3A Activity to Increase the Oral Bioavailability of Ibrutinib (2020) (0)
- Expansion and Characterization of Iovance Marrow Infiltrating Lymphocytes: A Potential Novel Therapeutic Strategy for the Treatment of Acute Myeloid Leukemia (2018) (0)
- Abstract 1111: SyntheticmicroRNA (miR)-181ananoparticles (NP) target RAS and sensitize cells to daunorubicin (DNR) in acute myeloid leukemia (AML) (2012) (0)
- Abstract 907: Bcl-xL dependence predicts response to alvocidib in chronic lymphocytic leukemia patients (2014) (0)
- Cl inic in Chronic Lymphocyt ic Leukemia : The Story of CAL-101 ( GS 1101 ) By (2012) (0)
- Rates of Preventable Hospitalization for Ambulatory Care Sensitive Conditions (ACSCs) among Patients with Lymphoid Malignancies (LM) (2008) (0)
- Therapeutic treatment of multi-organ system, obstructive pulmonary and scleradermatous chronic graft-versus-host disease with the BTK and ITK inhibitor Ibrutinib (TRAN3P.873) (2014) (0)
- Chemotherapy: New FluCam combination therapy has familiar limitations (2012) (0)
- Abstract B041: Ibrutinib treatment counteracts the immunosuppressive activity of malignant B cells (2016) (0)
- to alemtuzumab in chronic lymphocytic leukemia FCGR3A and FCGR2A polymorphisms may not correlate with response (2013) (0)
- Validation of CLL FISH Panel Scoring by Members of the Chronic Lymphocytic Leukemia Research Consortium. (2008) (0)
- In Vivo Quantification of Active Decitabine-Triphosphate Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (2012) (0)
- The Geldanamycin Derivative DMAG Demonstrates Improved Cytotoxicity and Down-Modulation of Hsp90 Client Proteins Relative to 17-AAG in Chronic Lymphocytic Leukemia (CLL) Cells: Justification for Clinical Trials in CLL. (2006) (0)
- Clonal hematopoiesis of indeterminate potential in the companion dog (2022) (0)
- A U.S.-based survey: The experiences of 1147 chronic lymphocytic leukemia (CLL) patients (pts). (2018) (0)
- A randomized phase II trial of maintenance versus consolidation bortezomib therapy following aggressive chemo-immunotherapy and autologous stem cell transplant for previously untreated mantle cell lymphoma. (2010) (0)
- New drugs 346 POSITIVE CORRELATION BETWEEN CIRCULATING NK CELLS AND DISEASE RESPONSE IN MANTLE CELL LYMPHOMA (MCL) TREATED WITH LENALIDOMIDE: FIRST IN VIVO DATA SUPPORTING NK-MEDIATED CYTOTOXICITY AS A MECHANISM OF ACTION (2011) (0)
- Abstract 276: Role of AP1 elements and TCL1 protein in regulation of the gene encoding PTPROt (protein tyrosine phosphatase receptor-type O) in chronic lymphocytic leukemia (2011) (0)
- Novel Mechanisms of Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia By Whole Genome Methylome Sequencing (2021) (0)
- Abstract B25: Progressive epigenetic programming during B cell maturation yields a continuum of clonal disease phenotypes with distinct etiologies in chronic lymphocytic leukemia. (2015) (0)
- Transcriptional up-Regulation of IL-21 Receptor-α On CLL Cells by CpG685 through An NF-κB Mediated Pathway Provides a Rationale for Combination Strategies with IL-21. (2009) (0)
- ROR1 Targeted Immunoliposomal Delivery of OSU-2S Show Selective Cytotoxicity in t(1;19) Translocated B-ALL (2019) (0)
- -refractory adult T-cell leukemia α load following alemtuzumab in AZT/IFN Durable hematological complete response and suppression of HTLV-1 viral (2013) (0)
- Phase 1 Study of Lumiliximabwith Detailed Pharmacokinetic and PharmacodynamicMeasurements in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (2007) (0)
- Methylation and silencing of the gene for the receptor-type protein tyrosine phosphatase PTPRO in primary human tumors (2005) (0)
- Zanubrutinib in Chronic Lymphocytic Leukemia. (2023) (0)
- Defining the role of Siglec-6-DOCK8 axis in cell adhesion and migration in Chronic Lymphocytic Leukemia (2021) (0)
- Second primary malignancies after chronic lymphocytic leukemia (2008) (0)
- Improved non-relapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced intensity conditioning allogeneic transplantation for hematologic malignancies (2014) (0)
- A phase I study of GTI-2040 (G), an antisense to ribonucleotide reductase (RNR), in combination with high-dose AraC (HiDAC) in acute myeloid leukemia (AML). (2006) (0)
- PF447 IOVANCE PERIPHERAL BLOOD LYMPHOCYTES (PBL): A POTENTIAL CELL THERAPY STRATEGY FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (2019) (0)
- Leukemia-initiating HSCs in chronic lymphocytic leukemia reveal clonal leukemogenesis and differential drug sensitivity. (2022) (0)
- Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance]) (2022) (0)
- Abstract 1824: EZH2 inhibition induces blast differentiation in acute myeloid leukemia (2022) (0)
- 39. Chronic lymphocytic leukemia with gain of 2p responds favorably to ibrutinib despite frequent co-occurrence with additional adverse cytogenetic markers (2021) (0)
- The Hsp90 Inhibitor 17-DMAG Increases SOCS3 and Regulates Cytokine Production, Migration and Cell Death in Chronic Lymphocytic Leukemia (2012) (0)
- FISH Analysis of CDKN2A/B Deletion in Chronic Lymphocytic Leukemia (2022) (0)
- Flavopiridol Decreases Mcl-1 and Initiates Early Mitochondrial Damage in Chronic Lymphocytic Leukemia (CLL) Cells. (2006) (0)
- Hematopoietic Progenitor Cell Transplantation for Treatment of Chronic Lymphocytic Leukemia (2010) (0)
- CLL-139: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naïve Chronic Lymphocytic Leukemia: ELEVATE-TN 4-Year Follow-up (2021) (0)
- Abstract 1882: Preclinical evaluation of the tyrosine kinase inhibitor ARQ 531 in AML (2018) (0)
- protein tyrosine phosphatase PTPROt in leukemia AP-1 elements and TCL1 protein regulate expression of the gene encoding (2012) (0)
- Early Fludarabine Treatment of TCL-1 Transgenic Mice Promotes Drug Resistance through a Mechanism Not Involving p53 Mutations: Implications for Patients with Chronic Lymphocytic Leukemia (CLL). (2007) (0)
- Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin9s Lymphoma, (2010) (0)
- Transducin b-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma (2020) (0)
- Change in tumor lysis syndrome risk after lead-in treatment in a phase 1b/2 study of obinutuzumab, ibrutinib, and venetoclax for chronic lymphocytic leukemia. (2018) (0)
- Abstract 3150:PLCG2C2-domain mutations co-occur withBTKandPLCG2resistance mutations in chronic lymphocytic leukemia undergoing treatment with the BTK inhibitor ibrutinib (2017) (0)
- Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic Micrornas (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (2019) (0)
- Final Results of the Phase 1/2 Study of Acalabrutinib Monotherapy in Treatment-Naive Chronic Lymphocytic Leukemia with >6 Years of Follow-up (2022) (0)
- PRMT5 Inhibition Modulates E2F1 and P53 to Restore Cell Cycle Regulation and Drive DNA Damage Response in Ibrutinib-Resistant Mantle Cell Lymphoma (2021) (0)
- Title: Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1 selective pressure in T-lymphocytes Short Title: Ibrutinib is an immunomodulatory ITK inhibitor (2016) (0)
- Karyotype Results From CpG Oligodeoxynucleotide Stimulated Chronic Lymphocytic Leukemia (CLL) Cultures Are Consistent Among Laboratories: a CLL Research Consortium (CRC) Study. (2009) (0)
- A Transgenic Mouse Model of Aggressive B-Cell Malignancy for Evaluating Anti-Human CD37 Therapeutics (2012) (0)
- The Expression of the GTPase-Deficient, Hematopoietic-Specific RhoH GTPase Is Implicated in Development of Chronic Lymphocytic Leukemia (CLL). (2007) (0)
- Modeling of the Epigenome of the Cell-of-Origin Identifies Cancer-Specific DNA Methylation Patterns in CLL (2018) (0)
- Plenary paper Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia (2006) (0)
- Activity and Tolerability of Ibrutinib in Combination With Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (2015) (0)
- The significance of BCL6 abnormalities on fluorescence in situ hybridization (FISH) in chronic lymphocytic leukemia (CLL). (2016) (0)
- Bifunctional degraders of cyclin dependent kinase 9 (CDK9): Probing the relationship between linker length, properties, and selective protein degradation. (2023) (0)
- Mutations in the Ras Pathway in Pre-Treatment Chronic Lymphocytic Leukemia Are Associated with VH1-69: Linking B-Cell Receptor Stereotypy to Downstream Signaling Events (2018) (0)
- Abstract 1721: Resistance to silvestrol is mediated by MDR1/Pgp over-expression in a lymphoblastic leukemia cell line and is reversible by treatment with rapamycin (2011) (0)
- Withaferin A is effective in inhibiting the survival of B cell lymphomas and chronic lymphocytic leukemias (P2052) (2013) (0)
- Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial (2021) (0)
- Long-Term Efficacy and Safety of Single-Agent Ibrutinib at 3 Years Follow-up in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL) (2015) (0)
- TCL1 Expression in Chronic Lymphocytic Leukemia Correlates with the Intensity of 11q Deletions and ZAP-70. (2007) (0)
- CCND1 and CCND2 Mutations Are Frequent in Adults with Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) with t(8;21)(q22;q22) (2016) (0)
- A validated ultrasensitive hybridization-ELISA assay for synthetic microRNAs in mouse plasma and human leukemia cells and its mouse pharmacokinetics (2008) (0)
- Cytotoxicity Contributes to Antibody-Dependent Cellular Human Monocytes by TLR 8 Agonists and Granzyme B Expression Is Enhanced in Butchar and Susheela (2015) (0)
- Fc engineered anti-CD33mAb potentiates cytotoxicity of mbIL-21 expanded NK-cells against primary AML pre-treated with decitabine (2019) (0)
- Comparative trial of aazacitidine versus conventional care in high risk MDS patients: Methodologic challenges in designing an international survival trial. (2003) (0)
- Title Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (2019) (0)
- Novel jumping translocations (JT) associated with genetic instability and aggressive disease in chronic lymphocytic leukemia (CLL). (2011) (0)
- Comment on Gruber et al , page 1175 UGT 2 B 17 as a disease accelerator in CLL---------------------------------------------------------------------------------------------------------------- (0)
- Acalabrutinib with Obinutuzumab in Treatment-Naive (TN) and Relapsed/Refractory (R/R) Patients with Chronic Lymphocytic Leukemia (CLL): 3-Year Follow-Up (2019) (0)
- Apoptotic-Regula tory a nd C omplement-Prote cting P rotein Expression i n C hronic L ymphocytic L eukemia: R elationship t o In V ivo R ituximab R esistance (2003) (0)
- MVA-TRICOM vaccine strategy makes CLL cells an attractive T-cell target (2005) (0)
- Change in T and NK Cell Counts (2008) (0)
- IN REPLY: The unacceptable toxicities seen in all four chronic lymphocytic leukemia (CLL) patients treated with lenalidomide at a (2008) (0)
- Refining our Understanding of the Genetic Variation in CLL (2013) (0)
- pathway in human chronic lymphocytic leukemia cells Hu1D10 induces apoptosis concurrent with activation of the AKT survival (2011) (0)
- Abstract 1964: Preclinical efficacy of the HSP90 inhibitor SNX-5422 in targeting C481S mutant BTK and ibrutinib resistant CLL (2018) (0)
- OSU-DY7, a Novel D -Tyrosinol Derivative, Mediates Cytotoxicity in Chronic Lymphocytic Leukemia and Lymphoblastic Lymphoma through p38 Mitogen-Activated Protein Kinase Pathway. (2009) (0)
- with p53 mutations and deletions Alemtuzumab is an effective therapy for chronic lymphocytic leukemia (2013) (0)
- Age and Sex Differences in the Eμ-TCL1 Adoptive Transfer Mouse Model of CLL (2022) (0)
- Defining the Biochemical Role of Sialic Acid-Binding Immunoglobulin-like Lectin-6 in Adhesion and Migration in Chronic Lymphocytic Leukemia (2021) (0)
- NFkB p50 (Nfkb1) Contributes to Disease in the Eu-TCL1 Mouse Model of Chronic Lymphocytic Leukemia (2015) (0)
- Rate of Clonal Hematopoiesis in Patients with Venous Thromboembolism (2021) (0)
- Multi-Trial Safety Evaluation of the Fully Antagonistic Human Anti-CD40 Monoclonal Antibody Lucatumumab (HCD122) in Patients with Relapsed or Refractory B-Cell Malignancies, (2011) (0)
- development tool for human chronic lymphocytic leukemia Characterization of the TCL-1 transgenic mouse as a preclinical drug (2013) (0)
- Comment on Dell ’ Agnola et al , page 4311 HSCs for muscular dystrophy : a paradigm shift (2004) (0)
- CD103 Deficiency Separates Graft-Versus-Host Disease And Graft-Versus-Leukemia Effects Mediated By Donor CD8 T Cells (2010) (0)
- Comparative Outcomes and Molecular Response Predictors of IDH1/2-Mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance) (2021) (0)
- Awareness, Knowledge, and Preferences of United States (US) Patients with Chronic Lymphocytic Leukemia (CLL) and Their Caregivers Related to Finite Duration (FD) Therapy and Minimal (Measurable) Residual Disease (MRD) (2021) (0)
- Mcl-1 as a Possible Predictor of Progression-Free Survival in Previously Untreated Chronic Lymphocytic Leukemia Patients Treated with Pentostatin, Cyclophosphamide and Rituximab. (2008) (0)
- Abstract 4925: Lymphocyte cytosolic protein 1 (LCP1) is a membrane-associated molecular target in chronic lymphocytic leukemia and is activated in microenvironment signaling. (2013) (0)
- IL-21-Expanded NK Cells As Autologous Cell Therapy for CLL (2019) (0)
- White Blood Cell Count (WBC) Levels Are Associated with Molecular Profiles and Are Independent Outcome Predictors in Acute Myeloid Leukemia (AML) Patients (Pts) (Alliance) (2021) (0)
- ROR1 targeted immunoliposomal delivery of OSU-2S shows selective cytotoxicity in t(1;19)(q23;p13) translocated B-cell acute lymphoblastic leukemia. (2022) (0)
- Abstract 6118: A primary mouse model of AML as a new way to screen novel therapeutics and treatment combinations (2020) (0)
- CD33 Targeted Immunoliposomal Delivery of OSU-2S, a Non-Immunosuppressive FTY720 Derivative, Mediates Selective Cytotoxicity in Acute Myeloid Leukemia (2016) (0)
- XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia. (2021) (0)
- Chronic graft-versus-host disease (cGVHD) is a life-threatening impediment to allogeneic hematopoietic stem cell transplantation, and current therapies do not completely prevent and/or treat cGVHD. CD4 (2014) (0)
- Abstract 2557: Immune modulating agent ibrutinib blocks T-helper 17 activation and release of IL-17A while preserving T-regulatory cell function (2014) (0)
- Intracellular Levels of Oblimersen Sodium and Target Downregulation Correlates to Clinical Activity of bcl-2 Antisense in Acute Myeoid Leukemia (AML). (2004) (0)
- Social Deprivation Independently Predicts Survival in Younger Patients with Acute Myeloid Leukemia (Alliance) (2021) (0)
- Abstract 4471: Novel SF3B1 deletion mutations result in aberrant RNA splicing in CLL patients (2017) (0)
- Toxicity in patients (pts) age 65 or older with dose-adjusted REPOCH (DA-REPOCH) for untreated diffuse large B-cell lymphoma (DLBCL). (2012) (0)
- Ibrutinib (PCI-32765) administration modulates a Th1 dominated immune response during cutaneous leishmaniasis infection (P3070) (2013) (0)
- Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma ( CSLL-1 Follicular Lymphoma ( FOLL-1 Mantle Cell Lymphoma ( MANT-1 Diffuse Large B-Cell Lymphoma ( BCEL-1 Burkitt Lymphoma ( BURK-1 Lymphoblastic (2010) (0)
- Changes in Clinical Stage Identify Different Response Categories Among Patients in Iwcll PR: Analysis of CLL Patients on the Resonate Study (2016) (0)
- High Surface Expression of CD49d (VLA-4) and CD79b Correlates with Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia (CLL) (2019) (0)
- FTY720 (2-Amino-2-[2-(4-octylphenyl) ethyl] Propane 1, 3-diol hydrochloride), Mediates Cytotoxicity through Caspase Independent and Protein Phosphatase 2A Dependent Mechanisms in Chronic Lymphocytic Leukemia and Lymphoblastic Leukemia/Lymphoma. (2006) (0)
- GlycoVariant Anti-CD37 Small Modular Immuno-Pharmaceutical Exhibits Superior Natural Killer Cell Mediated Cytotoxicity Against Chronic Lymphocytic Leukemia Cells at Low Concentrations and Low Antigen Density (2010) (0)
- Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma (2009) (0)
- Advances in genome-wide CLL linkage (2007) (0)
- Ibrutinib Treatment Improves T-Cell Proliferative Ability and Effector Function in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients (2018) (0)
- TLR7/8 Differentially Regulates Fcγ Receptor Expression and Function. (2009) (0)
- IL-21-Expanded Natural Killer Cells As Autologous Cell Therapy for CLL (2019) (0)
- Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia (2021) (0)
- Impaired Renal Function on Cholesterol Efflux Capacity, HDL Particle Number, and Cardiovascular Events (0)
- Improved Outcome of CLL Patients with Leukemic Clones Expressing Mutated IGHV May Not Be Due to An Inability to Bind (auto)Antigen In Vivo (2010) (0)
- Protein Tyrosine Phosphatase Receptor Type O (PTPRO) Exhibits Tumor Suppressor Properties in K562 Cells by Dephosphorylating Bcr-Abl. (2007) (0)
- Mixed‐Type Autoimmune Hemolytic Anemia following Fludarabine Treatment in a Patient with Chronic Lymphocytic Leukemia/Small Cell Lymphoma (1998) (0)
- Immunohistochemi-NCCN Diffuse Large B-Cell Lymphoma Version 1 . 2016 Clinical Practice Guidelines in Oncology (2016) (0)
- Abstract CT-06: The combination of bortezomib (BOR) and decitabine (DEC): A phase I trial in patients (pts) with acute myeloid leukemia (AML) targeting FLT3 expression (2012) (0)
- Distinct Gene Expression Profiles and Mutations Associate with Outcome in Younger Adults with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance) (2019) (0)
- VENTRICULAR ARRHYTHMIAS IN PATIENTS MANAGED WITH IBRUTINIB FOR CANCER IMMUNOTHERAPY (2018) (0)
- Pharmacokinetic and pharmacodynamic correlations of flavopiridol in the treatment of chronic lymphocytic leukemia. (2016) (0)
- Longitudinal Genomic Analyses In Chronic Lymphocytic Leukemia (CLL) Patients Reveal Clonal Relationship and Genomic Evolution In Disease Progression and After Therapy (2010) (0)
- Inhibiting the Inhibitors of Apoptosis: When Two Targets Are Better Than One. (2021) (0)
- TLR7/8 Agonists Overcome the Suppression of FcγR Activity in Monocytes From Chronic Lymphocytic Leukemia Patients (2012) (0)
- In Vitro and In Vivo Anti-Leukemic Effects of KPT-9274, a Reported PAK4 Allosteric Modulator, in Acute Myeloid Leukemia: Promising Results Justifying Further Development in This Disease (2015) (0)
- Hospital Care of Pathological Vertebral Fracture (PVF) in Multiple Myeloma (MM) Patients: Burden of Illness and Patterns of Care (2008) (0)
- COSMOS: MOR208 plus idelalisib or venetoclax in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyrosine kinase inhibitor (BTKi)—A two-cohort phase II study. (2017) (0)
- Effects of the Btk Inhibitor Ibrutinib on Monocyte Responses to Antibodies (2015) (0)
- Personalized Oncology in Acute Myeloid Leukemia (AML): Validation of the Prognostic Value of the Knowledge Bank Algorithm in Patients (Pts) Treated on Cancer and Leukemia Group B (CALGB)/Alliance Protocols (2019) (0)
- Normal FISH CLL Represents a Heterogeneous Subgroup Where Prognosis Can be Refined with IGHV Mutational Status (2021) (0)
- The importance of the BTK pathway in B-cell malignancies: discussion. (2013) (0)
- Abstract 492: Ibrutinib inhibits Interleukin-2 inducible kinase, driving a Th1 selective pressure in human leukemia patients that serves to alleviate tumor-induced immunosupression. (2013) (0)
- Significant in Vivo Efficacy of the SINE KPT-330 in Mouse Models of CLL. (2012) (0)
- Juxtaposing CD20 and CD74 with Novel Bispecific Antibodies Evokes Potent Cytotoxicity in Mantle Cell Lymphoma (MCL) (2011) (0)
- Cytogenetics for Treatment Stratification in De Novo Adult Acute Myeloid Leukemia (2003) (0)
- Ibrutinib Is effective in relapsed CLL (2013) (0)
- A Retrospective Observational Real-World Study of the Characteristics, Genomic Analysis, Treatment Patterns and Outcomes of Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the United States (2021) (0)
- lymphocytic leukemia cells and CD23+ lymphoma cell lines Mediation of apoptosis by and anti-tumor activity of lumiliximab in chronic (2013) (0)
- Generation and Analysis of Transgenic Mice Reveal a Role for CRE Binding Proteins in Multiple Stages of B Cell Development, Functional Maturation, Proliferation and Apoptosis. (2004) (0)
- IDELALISIB MONOTHERAPY RESULTS IN DURABLE RESPONSES IN PATIENTS WITH RELAPSED OR REFRACTORY WALDENSTROM'S MACROGLOBULINEMIA (WM) (2015) (0)
- PRMT5 Initiates an Epigenetic Program That Promotes Progression of Chronic Lymphocytic Leukemia (2017) (0)
- Investigation of Novel Initial Therapy for Chronic Lymphocytic Leukemia (2011) (0)
- Targeted Delivery of MicroRNA-29b by Nanoparticles Provides Antileukemic Activity and Increases Sensitivity to the Hypomethylating Agent Decitabine (DAC) in Acute Myeloid Leukemia (AML) (2011) (0)
- Multi-Dimensional Analysis of Adult Acute Myeloid Leukemia (AML) Landscape Cross-Continents Reveals Age Associated Trends in Mutations and Outcomes (2021) (0)
- High-dimensional genomic feature selection with the ordered stereotype logit model. (2022) (0)
- Clinical and Molecular Characteristics of Acute Myeloid Leukemia (AML) Patients with TP53 Mutations and TP73 Mutations (2018) (0)
- Genomic Profiling Identifies Novel Mutations and Fusion Genes in Newly Diagnosed and Relapsed Pediatric FLT3-ITD-Positive AML (2016) (0)
- Ingle-Institutional Experience with the Use of PD-1 Inhibitors for the Treatment of Richter's Syndrome (2017) (0)
- P525: PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF ENTOSPLETINIB ADDED TO INTENSIVE INDUCTION AND CONSOLIDATION CHEMOTHERAPY IN NEWLY DIAGNOSED NPM1-MUTATED AML (2022) (0)
- Results of a phase I trial of the proteasome inhibitor carfilzomib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL). (2013) (0)
- therapy for previously treated indolent non-Hodgkin lymphoma , as δ Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- (2014) (0)
- Abstract 4520: The effect of EPZ011989, an enhancer of Zeste homolog 2 inhibitor, in acute myeloid leukemia (2016) (0)
- A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2-Mutant AML Patients: 3-Year Follow-up (2022) (0)
- Meta-Analysis of Genome-Wide Association Studies of Acute Myeloid Leukemia (AML) Patients Identifies Variants Associated with Risk of 11q23/KMT2A-Translocated and Core-Binding Factor (CBF) AML and Suggests a Role for Transcription Elongation in Leukemogenesis (2020) (0)
- Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib (2016) (0)
- Genetic Inhibition of PI3K p110delta Antagonizes Survival Signals and Induces Immune Activation in Chronic Lymphocytic Leukemia (CLL) (2015) (0)
- Micro-RNA and Gene Expression In CLL: Network Analysis Elucidating the Complex Role of the NF-κB Signaling Pathway In Disease. (2010) (0)
- Abstract 3959: Ibrutinib immunomodulation via CTLA4 downregulation in CLL (2019) (0)
- myeloid leukemia in acute microRNA-181a up-regulates expression of the antileukemic -p30 protein α Lenalidomide-mediated enhanced translation of C/EBP (2013) (0)
- Enitociclib (VIP152/formerly BAY1251152) Is a Selective and Active CDK9 Inhibitor : Preliminary Safety and Early Signs of Efficacy in Patients with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (2022) (0)
- Mutation Patterns Identify Adult Patients with De Novo Acute Myeloid Leukemia (AML) Aged 60 Years or Older Who Respond Favorably to Standard Chemotherapy: an Analysis of Alliance Studies (2017) (0)
- Emerging drug profi le: cyclin-dependent kinase inhibitors (2013) (0)
- Complex Karyotype Predicts Poor Response To Salvage Therapy And Ineligibility For Reduced Intensity Conditioning Transplantation In CLL (2010) (0)
- Changing The Treatment Paradigm For Previously Treated Chronic Lymphocytic Leukemia Patients With Del(17p) Karyotype (2013) (0)
- Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL) (2021) (0)
- Global Assessment of Promoter Methylation in a Murine Model of Cancer Identifies ID4 as a Putative Novel Tumor Suppressor Gene in Human Leukemia. (2004) (0)
- Abstract 509: Immunoglobulin reactivity analysis of chronic lymphocytic leukemia patients unveils Lymphocyte Cytosolic Protein 1 (LCP1) as a novel CLL exosome antigen (2012) (0)
- Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML) (2012) (0)
- EFFECT OF SINGLE‐AGENT IBRUTINIB ON TUMOR DEBULKING AND REDUCTIONS IN TUMOR LYSIS SYNDROME (TLS) RISK IN PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) (2017) (0)
- Acute Myeloid Leukemia Interplay of RUNX 1 / MTG 8 and DNA Methyltransferase 1 in Updated (2005) (0)
- The ETS1 Transcription Factor Is Implicated in Human and Murine Intermediate NK Cell Development Stages (2018) (0)
- The Mutational Patterns Associated with Cytogenetic Subsets of De Novo Acute Myeloid Leukemia (AML): A Study of 1603 Adult Patients (Pts) (2016) (0)
- Natural Killer Cell Immune Reconstitution Predicts Outcomes for Patients with Chronic Lymphocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation (2008) (0)
- Combination therapy with etanercept and rituximab in relapsed CLL/SLL (2008) (0)
- Restoring Functional Deficits in Older Adults with Hematologic Malignancy (2019) (0)
- Study of VH3-21 in a Large Cohort of Chronic Lymphocytic Leukemia Patients Reveals Evidence for Antigen Selection and Confirms Its Predictive Value for Early Disease Progression. (2006) (0)
- Simultaneous Disruption of XPO1 and A20 in Murine B Cells Influences Both B and T Cell Repertoire (2021) (0)
- Elucidating the Mechanism of Action (MOA) of Navtemadlin, an MDM2 Inhibitor, and Its Synergy with Gilteritinib in Myeloid Malignancies (2022) (0)
- CLL-115: First Results of a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (2021) (0)
- Pre-Clinical Activity of a Novel FcγRIIIa Engineered CD19 Monoclonal Antibody in B Cell Chronic Lymphocytic Leukemia and Acute Lymphoblastic Leukemia. (2007) (0)
- The Relative Significance of ZAP -70 Promoter Methylation As a Prognostic Factor in Previously Untreated Chronic Lymphocytic Leukemia: Validation of Results Using a Second Large CLL Research Consortium (CRC) Patient Data Set (2012) (0)
- Genome-Wide Association Study (GWAS) Identifies a Significant Acute Myeloid Leukemia (AML) Susceptibility Locus Near BICRA (2018) (0)
- Autophagy Promotion With Obatoclax Overcomes Steroid Resistance in Pediatric ALL (2010) (0)
- Comment on Shukla et al , page 2848 IRF 4 2 / 2 Vh 11 mice : a novel mouse model of CLL---------------------------------------------------------------------------------------------------- - (2013) (0)
- CC-122 is more potent but transcriptionally mirrors Lenalidomide in Chronic Lymphocytic Leukemia (2017) (0)
- CLINICAL OUTCOMES OF PATIENTS WITH T‐CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA (T‐LGLL) AT THE OHIO STATE UNIVERSITY JAMES COMPREHENSIVE CANCER CENTER (OSU JAMES‐CCC) (2019) (0)
- Chronic Lymphocytic Leukemia: Introduction (2006) (0)
- Dic(17;18)(p11.2;p11.2) Is a Recurring Abnormality in Chronic Lymphocytic Leukemia Associated with Aggressive Disease. (2009) (0)
- Targeting PI3K signaling to ameliorate chronic graft versus host disease. (2016) (0)
- Chapter-39 Early Larynx Cancer (2016) (0)
- Analysis of 179 Patients with Newly Diagnosed Multiple Myeloma (MM) Treated with Novel Agents Followed by Autologous Stem Cell Transplantation (ASCT): a Retrospective Study (2010) (0)
- Abstract 3985: Characterization of plasma-derived exosomes in CLL reveals a distinct microRNA signature and the BCR regulation in exosome secretion (2015) (0)
- Abstract 4634: Population pharmacokinetic model of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the treatment of B-cell malignancies (2014) (0)
- Constitutive IL-10 production by normal and malignant B-1 cells is dependent on B cell receptor signaling (IRM10P.620) (2015) (0)
- Flavopiridol, Fludarabine and Rituximab (FFR): An Active Regimen in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma. (2008) (0)
- Combinatorial design of multiantibody-targeted immunolipopolyplex nanoparticles of oligonucleotides for leukemia therapy (2008) (0)
- Molecular and Cellular Pathobiology Extensive Promoter DNA Hypermethylation and Hypomethylation Is Associated with Aberrant MicroRNA Expression in Chronic Lymphocytic Leukemia (2012) (0)
- Proteomic profiling identifies specific histone species associated with leukemic and cancer cells (2015) (0)
- Abstract 371: Synthetic lethal and resistance pathways in midostaurin-treated AML (2019) (0)
- Abstract 1029: MAPK-mediated immunomodulation in disseminated murine Emu-TCL1 chronic lymphocytic leukemia (2017) (0)
- Adherence To The Ibrutinib 420 mg Dose Administered To Patients With Previously Treated CLL (2015) (0)
- Abstract B10: Genome-wide profiling reveals hyper- and hypomethylation at microRNA promoters in chronic lymphocytic leukemia (2012) (0)
- Rituximab Chemoimmunotherapy Transforms Old Treatment Paradigms for CLL by Improving Overall Survival (2011) (0)
- Conditioning with Fludarabine, Busulfan, and ATG Prior to Reduced-Intensity Allogeneic Stem Cell Transplant for CLL Is Associated with a Low Incidence of Acute Graft-Versus-Host Disease. (2010) (0)
- Genomic Integration of Adult and Pediatric Acute Myeloid Leukemia Reveals Age Dependent Risk Association (2022) (0)
- PKC Inhibitor AEB071 Demonstrates Pre-Clinical Activity In Chronic Lymphocytic Leukemia (2013) (0)
- Abstract CT021: Assessing clinical and pharmacodynamic (PD) profiles of patients (pts) with chronic lymphocytic leukemia (CLL) on ianalumab (VAY736) + ibrutinib (2023) (0)
- Biological Study of MG 98 , an Oligodeoxynucleotide Antisense to DNAMethyltransferase 1 , in Patients with High-RiskMyelodysplasia andAcuteMyeloid Leukemia (2008) (0)
- A Novel Ptpn11E76K/Npm1cA Murine Model of AML Identifies a Unique Immune Population Relevant to Human Disease (2022) (0)
- Refining prognosis in chronic lymphocytic leukemia with normal Fluorescence in situ hybridization results. (2023) (0)
- Abstract 5473: The contribution of P-glycoprotein to clinical pharmacokinetic interactions between lenalidomide and temsirolimus (2011) (0)
- IGHV and Interphase Cytogenetics in a Patient With Chronic Lymphocytic Leukemia. (2015) (0)
- INCIDENT HYPERTENSION AND CLINICAL OUTCOMES AFTER ACALABRUTINIB INITIATION FOR B-CELL MALIGNANCIES (2022) (0)
- Molecular Landscape and Clinical Features of Acute Myeloid Leukemia (AML) with Complex Karyotype (CK) (2017) (0)
- CLEAR: coverage-based limiting-cell experiment analysis for RNA-seq (2020) (0)
- LC-Facseq: A Novel Method for Detecting Rare Resistant Clones in Leukemia (2019) (0)
- NAMPT Inhibitor KPT-9274 Selectively Targets Self-Renewal Capacity in Acute Myeloid Leukemia (2018) (0)
- Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202. (2020) (0)
- High Early Death Rates, Treatment Resistance and Short Survival of Black Adolescent and Young Adults with Acute Myeloid Leukemia (2021) (0)
- Chapter 16 – Adult Burkitt's Lymphoma (2006) (0)
- Trial in Progress: Phase 1/2 Study Evaluating the Safety and Efficacy of Iov-2001, an Autologous, Non-Genetically Modified, Polyclonal T-Cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (2021) (0)
- O2-11-2Efficacy and safety in genetic and clinical subgroups: Phase III RESONATETM trial of ibrutinib vs ofatumumab in CLL/SLL (2015) (0)
- PF377 ACALABRUTINIB WITH OBINUTUZUMAB IN TREATMENT-NAIVE AND RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: 3-YEAR FOLLOW-UP (2019) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With John C Byrd?
John C Byrd is affiliated with the following schools:
